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Abstract
The rapid increase in antibiotic resistant infections and the slowing pace of antibiotic
development emphasize the need for alternative therapeutic agents to cure infectious diseases
especially those caused by multidrug-resistant (MDR) strains. Bacteria obtain resistance to
antibiotics through multiple mechanisms. One of intrinsic mechanisms of drug resistance is
persister formation, by which bacterial cells enter a metabolically inactive stage and become
highly tolerant to essentially all antibiotics, even at the concentrations that are hundreds of times
higher than the lethal dose required to kill normal planktonic cells of the same strain. Persister
cells in biofilms are even more difficult to kill due to the presence of an extracellular matrix that
can block or retard the penetration of antibiotics. Thus new antimicrobials that are effective
against these drug tolerant cells are urgently needed for infection control.
In this study, we characterized the antimicrobial activities of newly designed synthetic peptides
on Escherichia coli and Pseudomonas aeruginosa strains including regular planktonic cells and
those in biofilms and at the persister stages. Our results revealed that 2D-24, an RW-rich
dendrimeric peptide, can kill planktonic cells of both P. aeruginosa PAO1 and PDO300 (a
mucoid strain) in a dose-dependent manner. Killing effect on biofilm and persister cells was
observed at the concentrations without significant toxicity to IB3-1 cells originated from human
lung tissues.
We also demonstrated that TN-5, a 1,3,5-triazine derivative, has antimicrobial effects on E. coli
RP437, P. aeruginosa PAO1 and PDO300 cells, with a minimum inhibitory concentration (MIC)
of 12.8 µM, and kills regular planktonic cells of both species dose dependently. TN-5 was also
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found effective against persister and biofilm cells of both E. coli and P. aeruginosa; and
the killing of biofilm cells of the mucoid PDO300 was enhanced by alginate lyase.
To understand the effects of AMP charge on the killing effects, we modified the net charge of
calcitermin originated from human airway secretions, and tested the effects on E. coli and P.
aeruginosa planktonic and persister cells at different pH values. The neutral derivative of
calcitermin showed better killing effect on persister cells at pH 7.4.
Along with synthetic peptides, we also studied the membrane potential of persister cells with cell
sorting and flow cytometry techniques using potentiometric dyes. Persister cells showed lower
membrane potential along with lower efflux pump activities compared to normal cells. Based on
these findings, we tested the hypothesis that persister cells can be effectively killed by antibiotics
that are substrates of efflux pumps. Consistent with this hypothesis, erythromycin was
found effective in killing persister cells of E. coli while normal cells are resistant to it. This
higher killing activity of erythromycin was corroborated with higher erythromycin accumulation
in persister cells based on the results of Mass Spectrometry analysis.

Key words: antibiotic tolerance, antibiotic resistance, antimicrobial peptides, membrane
potential, persister cells, biofilm, killing, TN-5, 2D-24, Escherichia coli, Pseudomonas
aeruginosa.
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CHAPTER 1

LITERATURE REVIEW

A part of this chapter has been published as Ali Adem Bahar and Dacheng Ren. Antimicrobial
Peptides. Pharmaceuticals 2013, 6: 1543-1575.
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1.1 Current situation of antibiotic resistance and associated challenges
Antibiotics have been used to treat infectious diseases for the last 70 years [1] with a great
success in saving lives [2]. This achievement is considered as one of the most important
breakthroughs in modern medicine [3]. However over-prescription and misuse of these drugs
with unrestrained enthusiasm led to an unprecedented challenge to public health with the
emergence of bacterial multidrug resistant strains [4]. Acquisition of antibiotic resistance is
greatly aided by promiscuous transfer of conjugative plasmids, transposable elements and
integron systems, among bacterial cells that are not necessarily related [5,6].
Antibiotic resistance has been recognized as a global threat in 2013 by Centers for Disease
Control [7] and several strains are listed as primary targets of new therapeutics including P.
aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). Infections caused by
multidrug resistant bacteria are commonly associated with high mortality and health care costs
[8] with 2 million people infected 23,000 and deaths annually in the U.S. alone [9], costing $20
billion to the healthcare system according to Infectious Disease Society of America [10].
Moreover, antibiotic-resistant infections cost $35 billion indirectly due to societal impacts. On
average, each hospitalized patient with antibiotic resistant infection costs around $24,000 along
with two times higher mortality rate than regular patients [8].
In addition to the increasing rate of the bacterial resistance, the number of bacterial species with
antibiotic resistance has also been increasing. For example, the mortal sepsis rate caused by
MRSA was 4% in the U.K. 1991; while this ratio increased to 37% in 1999 [11]. In a study by
Kelman et al. in 2011, 69% of S. aureus isolates from meat products showed resistance to
tetracycline and only 23% of the total isolates were found to susceptible to tetracycline,
2

penicillin, ampicillin, methicillin, erythromycin, clindamycin, gentamicin, chloramphenicol,
oxacillin, cefoxitin, and quinupristin-dalfopristin antibiotics [12]. Another bacterial species
causing serious infections is the opportunistic pathogen Pseudomonas aeruginosa. This
bacterium can rapidly develop resistance to several classes of antibiotics through mobile genetic
elements. In some cases, this bacterium was found to even develop resistance during antibiotic
treatment of an infection [13].
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni,
Pseudomonas aeruginosa and Enterobacter, have been collectively named “the ESKAPE bugs”
since they have remarkable capabilities to resist antibiotics and cause lethal infections [14].
Alarmingly, some infections are even resistant to all antibiotics that are currently available [15].
In this research, we focused on two intrinsic mechanisms of antibiotic resistance; biofilm
formation and persistence. This rapid and alarming increase in antibiotic resistant infections and
the slowing pace of new antibiotic development [16] emphasize the needs for novel alternative
therapeutic agents to cure infectious diseases especially those caused by multidrug-resistant
(MDR) bacteria.
Biofilms are multicellular structures of bacteria embedded in an extracellular polymeric
substance (EPS) matrix [17]; and persister cells are metabolically inactive dormant phenotypic
variants of bacterial cells that are highly tolerant to essentially all antibiotics [18]. These intrinsic
tolerance mechanisms play major roles in the recalcitrance of chronic infections, such as the lung
infections in cystic fibrosis patients [19].
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1.2 Mechanisms of antibiotic; acquired vs. intrinsic
1.2.1 Acquired resistance
Acquired resistance is based on genetic elements that allow bacteria to survive the attack by a
specific antibiotic and closely related agents [7,20]. Bacteria can acquire specific resistance
genes via transformation (uptake of extracellular DNA elements), transduction (through viruses
or phages) conjugation (horizontal gene transfer from another bacteria) or genetic mutation
during growth [21].
The products of these genetic elements cause antibiotic resistance by degrading antibiotics,
modifying the drug targets or quickly removing them from the cytosol. For example β-lactam
antibiotics, such as penicillins are cleaved by β-lactamases in P. aeruginosa [22]. The
widespread use of β-lactam antibiotics has caused the widespread of this gene among other
bacteria such as K. pneumoniae, Salmonella spp. and P. mirabilis.

1.2.2 Intrinsic tolerance
Compared to acquired mechanisms that are against specific antibiotics, intrinsic mechanisms
allow cells to tolerate a wide spectrum of different antimicrobials. Here we review three major
examples; drug efflux, biofilm formation and persistence.

1.2.2.1 Bacterial transport proteins: efflux pumps and porins
Bacterial efflux pumps are substrate-specific protein transporters, which are located in the
membrane and responsible for moving certain type of compounds, such as toxic metabolites and
antibiotics, out of the cell [23]. These pumps are found in both Gram-negative and Gram-positive
4

bacteria and they can extrude virtually all clinically relevant antibiotics from cytosol to the
external environment [24]. Efflux pumps require energy in the form of either ATP (originated
from proton motive force) or ion gradient (Na+ or H+) across the cell membrane to extrude
antibiotics [25].
There are five known classes of efflux pumps in Gram-negative bacteria [26] (Fig. 1.1): ATPbinding cassette family (ABC), multi antimicrobial extrusion protein family (MATE), small
multidrug resistance family (SMR), resistance-nodulation-division (RND) family, and major
facilitator superfamily (MFS) [26]. For example, 7 different efflux pumps have been identified in
P. aeruginosa for transporting tetracycline, β-lactam, fluoroquinolones antibiotics, metal ions
[27], small acylated homoserine lactones molecules [28], and quinolone signals [29].

Figure 1-1. Schematic representation of membrane transport proteins causing antibiotic
resistance. (A); porins, (B); ATP-binding cassette family and multidrug (ABC) family, (C); multi
antimicrobial extrusion protein (MATE) family, (D); small multidrug resistance (SMR) family
and major facilitator superfamily (MFS), (E); resistance-nodulation-division (RND) family.
5

The other type of transport proteins related to antimicrobial resistance is porin proteins mainly
present in the outer membrane of Gram-negative bacteria. Porins play an important role in the
semi-permeability of the membrane with unique channels for transporting small and charged
molecules. These cylindrical shaped tubes are composed of β-strands while polar residues face
inward into the aqueous channel and nonpolar residues face outward to interact with nonpolar
lipid membrane [30].

1.2.2.2 Biofilm and persister formation

Biofilms are complex multicellular structures of bacteria [31] which protect bacteria against
antimicrobial

therapies

and

adverse

environmental

conditions.

Extracellular

DNA,

polysaccharides, and fatty acids are some of the major components of the biofilm matrix
macromolecules, which help to maintain the biofilm structure and facilitate the development of
biofilm [32]. During biofilm formation, free swimming bacterial cells attach to a surface
reversibly and form small cell clusters first. These small cell clusters then secrete
polysaccharides and form the mature biofilm structure with large cell aggregates and water
channels between cell clusters.
The multicellular biofilm structure protects bacterial cells from antimicrobials, immune factors
and environmental toxins. For example, these biofilm cells exhibit up to 1000 higher tolerance to
antibiotics compared to normal planktonic cells [33]; and biofilms are associated with more than
80% of human infections [34] with high mortality [35] such as cystic fibrosis [36].
In addition to the multicellular structure, biofilms also host a large number of persister cells
which are phenotypic variants with inactive metabolism and thus high tolerance to antimicrobials
6

[37]. Persister cells are a small group of cells with no extra genetic modification for drug
resistance [19]. Unbalanced toxins/anti-toxins production [38-41] and stress response and
translation inhibition are known characteristics of persister cells [19,42]. These small group of
cells can survive through the antibiotic course and form the normal population with similar
percentage of persister cells again when the conditions turns back to normal for bacterial survival
[43]. This repopulation ability provides higher level of antibiotic tolerance and chance to develop
acquired resistance for bacterial cells [43]. Therefore, targeting persister cells will help for a
better treatment of chronic infections caused by multidrug resistant bacteria [44].
Because of the essential functions of cell membranes, antimicrobial agents targeting cell
membranes have good potential for persister controls. One class of such agents is antimicrobial
peptides (AMP). AMPs are oligopeptides with a varying number (from five to over a hundred) of
amino acids with a broad spectrum of targeted organisms ranging from viruses to parasites. Most
of the AMPs are membrane-active agents, which are positively charged, and act on negatively
charged phospholipid bilayer of bacterial membrane [45] where main energy synthesis and many
other important function occurs. It has been reported that some AMPs can sensitize bacteria by
depolarizing the membrane at sub-lethal concentrations [46] and resistance against such
antibacterial agents is difficult to acquire [47].

1.3 Antimicrobial peptides
Due to rapid development of bacterial resistance to conventional antibiotics, antimicrobial
peptides (AMPs), have received increasing attention as an alternative way of fighting against
antibiotic resistance. AMPs are a growing class of natural and synthetic peptides with a wide
spectrum of targets including viruses, bacteria, fungi, and parasites. In this section, we
7

summarize the major types of AMPs, their modes of action, and the common mechanisms of
AMP resistance. In addition, we discuss the principles for designing effective AMPs and the
potential of using AMPs to control biofilms and persister cells.

1.3.1 Sources and history of antimicrobial peptides

Historically AMPs have also been referred to as cationic host defense peptides [48], anionic
antimicrobial peptides/proteins [49], cationic amphipathic peptides [50], cationic AMPs [51],
host defense peptides [52], and α-helical antimicrobial peptides [53].
The discovery of AMPs dates back to 1939, when Dubos [54-55] extracted an antimicrobial
agent from a soil Bacillus strain. This extract was demonstrated to protect mice from
pneumococcal infection. In the following year, Hotchkiss and Dubos [56] fractionated this
extract and identified an AMP which was named gramicidin. Despite some reported toxicity
associated with intraperitoneal application [56], gramicidin was found effective for topical
treatment of wounds and ulcers [57]. In 1941, another AMP, tyrocidine, was discovered and
found to be effective against both Gram-negative and Gram-positive bacteria [58]. However,
tyrocidine exhibited toxicity to human blood cells [59]. In the same year, another AMP was
isolated from a plant Triticumaestivum [60], which was later named purothionin and found
effective against fungi and some pathogenic bacteria [61].
The first reported animal-originated AMP is defensin, which was isolated from rabbit leukocytes
in 1956 [62]. In the following years, bombinin from epithelia [63] and lactoferrin from cow milk
[64] were both described. During the same time, it was also proven that human leukocytes
contain AMPs in their lysosomes [65].
8

In total, more than 5,000 AMPs have been discovered or synthesized up to date [66]. Natural
AMPs can be found in both prokaryotes (e.g., bacteria) and eukaryotes (e.g., protozoan, fungi,
plants, insects, and animals) [67, 68-70]. In animals, AMPs are mostly found in the tissues and
organs that are exposed to airborne pathogens; and are believed to be the first line of the innate
immune defense [71,72] against viruses, bacteria, and fungi [68]. Thus, AMPs play an important
role in stopping most infections before they cause any symptoms. For example, frog skin is the
source of more than 300 different AMPs [67,73]. Most AMPs are produced by specific cells at all
times, while the production of some AMPs is inducible. For example, using silk moth as a model
system, Hultmark and colleagues [74] demonstrated that P9A and P9B can be induced in
hemolymph by vaccination with Enterobacter cloacae. In another study [75], epithelial cells
from different tissues of mice showed increased rate of mRNA transcription for defensin
production after infection with Pseudomonas aeruginosa PAO1.
Several types of eukaryotic cells are involved in AMP production such as lymphs, epithelial cells
in gastrointestinal and genitourinary systems [76,77], phagocytes [78], and lymphocytes of the
immune system [68,79]. In addition to direct involvement in innate immunity, AMPs have also
been found to influence host’s inflammatory responses during an infection [80-82]. It is known
that lipopolysaccharide (LPS) molecules, released from bacteria as a result of antibiotic
treatment or host immunity, can induce AMP production in mammals [78]. For example,
HEK293 cells produce defensin in response to LPS stimulation [83]. Some AMPs (e.g., CAP18
[84], CAP35 [85], and a lactoferrin-derivative [86]) can also block LPS-induced cytokine release
by macrophages. Thus, these AMPs can reduce inflammatory response. In comparison,
antibiotics do not have this type of regulation on inflammatory response of the host immune
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system; and LPS secretion following antibiotic treatment might cause over-reaction of the host
immune system. In some extreme cases, this can even lead to sepsis [78,87].

1.3.2 Structure and major activities of AMPs
Most AMPs reported to date can be characterized as one of the following four types based on
their secondary structures: β-sheet, α-helix, extended, and loop. Among these structural groups,
α-helix and β-sheet structures are more common [88]; and α-helical peptides are the most studied
AMPs to date. In α-helix structures the distance between two adjacent amino acids is around 0.15
nm and the angle between them with regard to the center is around 100 degree from the top view
(Fig. 1-2A). The best known examples of such AMPs are protegrin, magainin, cyclic indolicin,
and coiled indolicin [53]. β-sheet peptides are composed of at least two β-strands with disulfide
bonds between these strands [89].

Figure 1-2. Schematic representation of an α-helical AMP. This figure assumes the same α-helix
propensity for all amino acids in the peptide structure. (A) Helical wheel projection of the AMP
(top view). The angle between two consecutive amino acids in the sequence is 100 degree.
Dotted lines show two adjacent amino acids in the primary structure. (B) Side view of the
peptide. The distance between two adjacent amino acids, “n”, is 0.15 nm.
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Some AMPs do not belong to any of these groups [90]. Some AMPs contain two different
structural components [91]. Also, many peptides form their active structure only when they
interact with the membranes of target cells. For example, indolicin shows globular and
amphipathic conformation in aqueous solutions, while it is wedge-shaped in lipid bilayer
mimicking environments [92]. This AMP also changes its conformation during interaction with
DNA evidenced with decreased fluorescence intensity and a slight shift in the wavelength of
maximum emission [93].
Unlikely antibiotics, which target specific cellular activities (e.g., synthesis of DNA, protein, or
cell wall), AMPs target the lipopolysaccharide layer of cell membrane, which is ubiquitous in
microorganisms. Having a high level of cholesterol and low anionic charge puts eukaryotic cells
out of the target range of many AMPs [94].
Another important feature of AMPs is their rapid killing effect. Some AMPs can kill in seconds
after the initial contact with cell membrane [95]. AMPs are also known to enhance the activities
of antibiotics through synergistic effects. For example, the combination of penicillin with
pediocin and ampicillin with nisin Z exhibited killing of Pseudomonas fluorescens with 13- and
155-fold lower minimum inhibitory concentration (MIC), respectively, compared to using
antibiotics alone [96].
Because AMPs are made with amino acids, it is relatively easy to modify the structure (including
library construction and screening) and immobilize AMPs on surfaces [97]. It is possible to make
fully synthetic peptides by chemical synthesis [98] or by using recombinant expression systems
[99,100]. These artificial sources of AMPs are useful for modification of existing AMPs and for
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designing new synthetic AMPs. Such modifications have potential to change the targets of AMPs
and improve the stability of AMPs against proteases [101].
Despite these advantageous features of AMPs, there are still some challenges to their
applications, such as potential toxicity to humans [59,102,103], sensitivity to harsh
environmental conditions (susceptibility to proteases and extreme pH [104,105]), lack of
selectivity against specific strains [106], high production costs [107], folding issues of some
large AMPs [108], reduced activity when used for surface coating [109], and bacterial resistance
to some AMPs [110,111]. In the following section we will discuss the modes of actions of AMPs
and the current efforts to address the above challenges.

1.3.3 Major categories of AMPs and mechanisms of action

1.3.3.1 Classification

In general, enzymatic mechanisms are not involved in the antimicrobial activities of AMPs
[112]. For example, even though lysozyme is a monomeric peptide, it is not classified as an
AMP because it is relatively large (148 aa) and kills bacteria through enzymatic activities by
breaking 1,4-β-linkages in peptidoglycan chains [113]. Here, we categorize AMPs based on their
target and mode of action. For natural AMPs, we will focus on those from eukaryotes, especially
mammals.
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1.3.3.1.1 Antiviral peptides
Antiviral AMPs neutralize viruses by integrating in either the viral envelope or the host cell
membrane. Previous studies have shown that both enveloped RNA and DNA viruses can be
targeted by antiviral AMPs [114,115]. AMPs can integrate into viral envelopes and cause
membrane instability, rendering the viruses unable to infect host cells [116,117]. AMPs can also
reduce the binding of viruses to host cells [118]. For example, defensins bind to the viral
glycoproteins making herpes simplex viruses (HSV) unable to bind to the surface of host cells
[119].
Besides disruption of viral envelopes and blocking viral receptors, some antiviral AMPs can
prevent viral particles from entering host cells by occupying specific receptors on mammalian
cells [120,121]. For example, heparan sulfate is important for the attachment of HSV viral
particles to the host cell surface [122]. The heparan sulfate molecules are negatively charged
glycosaminoglycan molecules [123]. Thus, some α-helical cationic peptides, e.g., lactoferrin
[124], can prevent HSV infections by binding to heparan molecules and blocking virus-receptor
interactions [125].
Compared to the above AMPs that target viral receptors on cell surface, some AMPs do not
compete with viral glycoproteins for binding to the heparansulphate receptors on cell surface.
Instead, these antiviral AMPs can cross the cell membrane and localize in the cytoplasm and
organelles, causing changes in the gene expression profile of the host cells, which can help the
host defense system fight against viruses or block viral gene expression. For example, NP-1, an
AMP from rabbit neutrophils, prevents Vero and CaSki cell lines from infection by herpes
simplex viruses type 2 (HSV-2). This AMP stops the viruses by preventing the migration of a
13

major viral protein, VP16, into the nucleus. This viral protein is required to form complexes with
the host transcriptional factors to induce the expression of immediate early viral genes, which are
required for the virus to defeat the first stage cellular response [126]. Thus, this AMP does not
compete with viral particles to bind to the receptor on cell surface but it prevents cell-to-cell
spread of viral particles [127].

1.3.3.1.2 Antibacterial peptides
Antibacterial AMPs are the most studied AMPs to date and most of them are cationic AMPs,
which target bacterial cell membranes and cause disintegration of the lipid bilayer structure
[128,129]. The majority of these AMPs are also amphipathic with both hydrophilic and
hydrophobic domains. Such structures provide AMPs the capability to bind to lipid components
(hydrophobic region) and phospholipid groups (hydrophilic region) [94].
Interestingly, researchers have demonstrated that some AMPs at low concentrations can kill
bacteria without changing the membrane integrity. Instead of directly interacting with the
membrane, these AMPs kill bacteria by inhibiting some important pathways inside the cell such
as DNA replication and protein synthesis [130]. For example, buforin II can diffuse into cells
and bind to DNA and RNA without damaging the cell membrane [131]. Drosocin, pyrrhocoricin,
and apidaecin are other examples of such AMPs. These AMPs have 18–20 amino acid residues
with an active site for their intracellular target [132,133].
In some cases, certain AMPs have been shown to kill antibiotic resistant bacteria. For example,
both nisin (an AMP) and vancomycin (an antibiotic), can block cell wall synthesis. However, a
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methicillin resistant Staphylococcus aureus (MRSA) strain was reported to be resistant to
vancomycin, while it is still sensitive to nisin [134].

1.3.3.1.3 Antifungal peptides
Like antibacterial AMPs, antifungal peptides can kill fungi by targeting either the cell wall
[135,136] or intracellular components [137]. However, bacterial membrane and fungi cell wall
have different contents. For example, chitin is one of the major components of fungal cell walls
and some of antifungal peptides are capable of binding to chitin [138-140]. Such binding ability
helps AMPs to target fungal cells efficiently. Cell wall targeting-antifungal AMPs kill the target
cells by disrupting the integrity of fungal membranes [141,142], by increasing permeabilization
of the plasma membrane [143], or by forming pores directly [144].
Although the majority of antifungal AMPs have polar and neutral amino acids in their structures,
[94] there does not appear to be a clear correlation between the structure of an AMP and the type
of cells that it targets. For example, antifungal peptides have members from different structure
classes such as α-helical (D-V13K [145] and P18 [146]), extended (indolicin [147]), and β-sheet
(defensins [148]).

1.3.3.1.4 Antiparasitic peptides
Antiparasitic peptides are a smaller group compared to other three AMP classes. The first
antiparasitic peptide reported is magainin, which is able to kill Paramecium caudatum [149].
Later, a synthetic peptide was developed against Leishmania parasite [150]. Another example of
antiparasitic peptide is cathelicidin, which is able to kill Caernohabditis elegans by forming
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pores in the cell membrane [151]. Even though some parasitic microorganisms are multicellular,
the mode of action of antiparasitic peptides is the same as other AMPs. They kill cells by directly
interacting with cell membrane [151].

1.3.3.2 Mechanism of action
As described above, AMPs kill cells by disrupting membrane integrity (via interaction with
negatively charged cell membrane), by inhibiting proteins, DNA and RNA synthesis, or by
interacting with certain intracellular targets. All AMPs known by the late-90s are cationic.
However, the concept that AMPs need to be cationic was changed later with the discovery of
negatively charged AMPs in 1997 [152]. For example maximin-H5 [153] from frog skin and
dermicidin [154] secreted from sweat gland tissues of human are both anionic peptides.
Generally an AMP is only effective against one class of microorganisms (e.g., bacteria or fungi)
[78]. However, there are exceptions and some AMPs are known to have different modes of
action against different types of microorganisms. For example, indolicidin can kill bacteria,
fungi, and HIV [116,155]. It exhibits antifungal activities by causing damages to cell membrane
[147]. However, it kills E. coli by penetrating into the cells and inhibiting DNA synthesis [156];
and it shows anti-HIV activities by inhibiting HIV-integrase [157]. In comparison; some AMPs
have the same mode of killing of different cell types. For example, PMAP-23 can kill both fungi
and parasites by forming pores in their cell membranes [151,158].
One third of the total proteins of a bacterial cell are associated with the membrane and these
proteins have many functions that are critical to the cell including active transport of nutrients,
respiration, proton motive force, ATP generation, and intercellular communication [159]. The
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function of these proteins can be altered with AMP treatment even if complete cell lysis does not
occur. Therefore, AMPs’ rapid killing effect does not only come from membrane disruption but
can also come from inhibition of these functional proteins.

1.3.3.2.1 Membrane-active AMPs
Even if intracellular targets are involved, an initial cell membrane interaction with peptides is
required for the antimicrobial activities of AMPs [160]; and this interaction determines the
spectrum of target cells. Most membrane-active AMPs are amphipathic, which means that they
have both cationic and hydrophobic faces. This feature ensures the initial electrostatic interaction
with the negatively charged cell membrane and the insertion into membrane interior. The actions
of AMPs do not stop after this initial interaction. The hydrophobic part of an AMP helps insert
the AMP molecule into the cell membrane [161]. So the interaction mainly includes ionic and
hydrophobic interactions. These interactions mostly depend on two properties, e.g., cationic state
and hydrophobicity of the peptide. The major types of membrane-active AMPs and the
mechanisms of their actions are summarized in Table 1-1 and Figure 1-3.
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Table 1-1. The action mechanisms of membrane-active AMPs.

Interaction
model

Carpet like
(Detergent-like)

Membrane
thinning

Mechanism

The peptide micelle touches the membrane first and coats
a small area of the membrane. Then AMP molecules
penetrate the lipid bilayer to let pore formation leaving
holes behind.
AMPs insert themselves into only one side of the lipid
bilayer. It can form a gap between lipid molecules at the
chain region. This gap creates a force and pulls the
neighboring lipid molecules to fill it.

References

[162-164]

[165-167]

Aggregate

AMPs stick to the membrane parallel to the surface.
Then reorientation of AMPs occurs and they insert
themselves into the membrane vertically to form spherelike structures.

Toroidal pore

AMPs align perpendicularly into the bilayer structure
with their hydrophobic regions associated with the center
part of the lipid bilayer and their hydrophilic regions
facing the pore.

Barrel-stave

Staves are formed first parallel to the cell membrane.
[129,171,172]
Then barrels are formed and AMPs are inserted
perpendicularly to the plane of the membrane bilayer.
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[162,168170]

[130,170]

Figure 1-3. Schematic representation of some action mechanisms of membrane-active AMPs. (A)
Barrel-Stave model. AMP molecules insert themselves into the membrane perpendicularly. (B)
Carpet model. Small areas of the membrane are coated with AMP molecules with hydrophobic
sides facing inward leaving pores behind in the membrane. (C) Toroidal pore model. This model
resembles the Barrel-stave model, but AMPs are always in contact with phospholipid head
groups of the membrane. The blue color represents the hydrophobic portions of AMPs, while the
red color represents the hydrophilic parts of the AMPs.
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1.3.3.2.2 Intracellularly active AMPs
In early AMP studies, permeabilization of bacterial cell membrane by AMP was thought as the
primary mechanism of killing. It was suggested that AMPs should be used at concentrations high
enough so that they can kill microorganisms by disrupting the membrane with sufficient
channels and pores [173]. However, some AMPs were found to start membrane permeabilization
at concentrations lower than their MICs, while others could only do so at concentrations higher
than their MICs. The finding that some AMPs can kill their target cells without causing
membrane permeabilization suggests that there may be other mechanisms of killing. Recently,
intracellularly active AMPs have been shown to interact with targets inside the cells [174-176].
For example indolicin was shown to bind to DNA with a preferred sequence [93,177].
Some AMPs can inhibit DNA and protein synthesis [178,179]. One example of this is PR-39, an
AMP from pig intestines, which kills bacteria in a non-lytic process by acting like a proteolytic
agent and stopping protein and DNA synthesis [180]. Similar to PR-39, indolicin does not lyse
cells directly. It enters the cytoplasm and kills bacterial cells by targeting DNA synthesis [156]
[178]. Also, some human immune system derived AMPs such as tPMP-1 and aHNP-1 inhibit
DNA and protein synthesis within an hour after they enter the cells [181]. Apidaecin is another
protein synthesis blocking AMP which lacks pore forming ability. This AMP is only effective
against Gram-negative bacteria. It is suggested that this AMP is actively transported with a
transporter protein and then it blocks protein synthesis with a series of molecular interactions
with different targets [182].
Some AMPs can also inhibit proteases of microbes. For example, histatin 5 stops the periodontal
tissue destruction by inhibiting a protease from Bacteriocides gingivalis [183]; and eNAP-2 has
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anti-protease activities against microbial serin proteases [184]. Interestingly, there are some
intracellular AMPs which can only kill cells at certain growth stages. For example, diptericin is
only effective against actively growing bacterial cells, suggesting it may interact with certain
specific metabolic pathways during bacterial growth [185,186].
Among these intracellularly active AMPs, some of them have multiple targets. For example
seminalplasmin inhibits RNA polymerase and can stop RNA synthesis completely at
concentrations lower than many other antibacterial agents [187]. On the other hand, the same
AMP can activate an autolysin protein inside the target cells leading to autolysis [188,189].
Inhibition of intracellular pathways by AMPs [173,178] suggests that there might be mechanisms
of cellular uptake of AMPs. Two such mechanisms have been reported: direct penetration and
endocystosis [161]. According to Jones [190], cellular uptake of AMPs can take place through
endocytosis, which includes macropinocytosis and receptor mediated endocytosis. In
macropinocytosis, the cell membrane folds inward and forms vesicles with the help of dynamin
proteins. These vesicles are called macropinosomes and they are like small cells with only a
membrane around them [161]. In receptor mediated endocytosis, a part of the membrane is
coated with clathrin or caveolin proteins followed by pit formation. Later, these pits bud from the
membrane to inner side of the cell and form vesicles [190,191].

1.3.4 Designing new synthetic AMPs: major factors to consider
To date, no data have been reported to demonstrate a clear relationship between the structural
groups of an AMP and its mode of action, the degree of activity, or the host range. Even the
AMPs with very similar structures can have drastically different mechanisms of action and the

21

range of targeted cells [94]. For example, buforin targets DNA and RNA; while magainin 2, an
AMP with similar structure, targets the cell membrane causing cell lysis [192,193]. Although a
structure-based precise prediction of activity, mode of action, and host range may not be
possible, certain general design principles have been proposed by previous studies. The AMP
structure is certainly important, while the size, charge, hydrophobicity, amphipathicity, and
solubility are all crucial physiochemical properties for their antimicrobial activities and target
specificity of AMPs [194]. Changing these features will help to modify the activity and target
spectrum of AMPs.

1.3.4.1 Important physiochemical properties of AMPs

1.3.4.1.1 Length
The length of an AMP is important to its activity because at least 7–8 amino acids are needed to
form amphipathic structures with hydrophobic and hydrophilic faces on opposite sides of a
peptide molecule. The size for an AMP to transverse the lipid bilayer of bacteria in the barrelstave model should be at least 22 amino acids for α-helical AMPs, while eight amino acids are
needed for β-sheet AMPs [195]. Besides the effects of length on its 3D structure and mode of
action, the length of an AMP may also affect its cytotoxicity. For example, a shortened melittin
with 15 residues at its C-terminal [196] and a shorter derivative of HP(2-20) [197] exhibited at
least 300 times less toxicity to rat erythrocytes and human erythrocytes, respectively, compared
to their original forms. Therefore, the length of AMP should be taken into consideration when
designing new synthetic peptides with low toxicity.
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1.3.4.1.2 Net charge
The net charge of known AMPs, which is the sum of all charges of ionizable groups of the
peptide, varies from negative to positive and it is the main factor for the initial interaction with
negatively charged cell membranes. By changing the net charge of an AMP, its antimicrobial and
hemolytic activities can be altered to achieve selective killing of microbes with no or minimized
effects on host cells. For example, increasing positive net charge of V13K from +8 to +9 resulted
in higher hemolytic activity, while decreasing the net charge to lower than +4 abolished its
activity against P. aeruginosa [145].

1.3.4.1.3 Helicity
Helicity represents the ability of an AMP to form spin structure. It is less important for the
activity of an AMP compared to other factors discussed above. However, it is important for
determining the toxicity on eukaryotic cells [53]. Reducing helicity by incorporating D-amino
acids into the primary sequence has been shown to lower the hemolytic effect, while the
antimicrobial effect was retained [198]. For example, Papo et al. [101] modified some α-helical
peptides by replacing 35% of the L-amino acids with D-amino acids and found that this
modification eliminated the hemolytic activity. Besides, these new synthetic AMPs are not
sensitive to proteases. Therefore, incorporating D-amino acids to change helicity is a useful
strategy for designing new synthetic peptides with less hemolytic activity and enhanced stability
against proteolytic cleavage. Another important factor associated with the helicity of AMP is the
helix propensity of each amino acid in the primary sequence. For example, proline and glycine
have lower helix-forming propensities compared to other amino acids [199]. Thus, these residues
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are not preferred when designing α-helical AMPs. In addition, peptides should be flexible
enough to change their conformation during the membrane insertion process [94].

1.3.4.1.4 Hydrophobicity
Hydrophobicity has also been shown to influence the activity and selectivity of AMP molecules.
Almost 50% of amino acids in the primary sequence of natural AMPs are hydrophobic residues
[194]. In most cases, increase in hydrophobicity on the positively charged side of an AMP below
a threshold can increase its antimicrobial activity [53], while decreasing hydrophobicity can
reduce antimicrobial activity [200]. There appears to be an optimal hydrophobicity for each
AMP, beyond which its activity decreases rapidly [176]. Therefore, when designing new
synthetic peptides, the hydrophobicity should be selected within an optimal window. Some
previous studies have shown that hydrophobicity is also critical for determining the range of
target cells of an AMP. Increasing the hydrophobicity of an AMP can change the range of targets
[201,202]. For example, magainin is an AMP that is only effective against Gram-negative
bacteria. However, some synthetic analogs with higher hydrophobicity can also kill some Grampositive bacteria and eukaryotic cells [203].

1.3.4.1.5 Amphipathicity
Amphipathicity is another important property of AMPs to ensure their activity and interaction
with microbial membranes. Fernandes-Vidal et al. [204] showed that amphipathicity is more
important than hydrophobicity for binding to microbial membranes. Because amphipathicity of
AMPs is required for a strong partition into the membrane interface, priority should be given to
the amphipathic structure when designing synthetic AMPs for specific target cells.
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1.3.4.1.6 Solubility

Since AMPs should act on or enter through lipid membranes, they need to be soluble in aqueous
environments. If AMP molecules aggregate, it will lose its ability to interact with the cell
membrane. For example, a hybrid synthetic AMP composed of cecropin and melittin has a
tendency to form dimers. Substituting a Lys (L) residue on the non-polar face of this hybrid
AMP prevents dimerization and leads to reduced hemolytic activity. Losing dimerization ability
makes this AMP more effective for its incorporation into microbial membranes [205]. This
example demonstrates the importance of solubility and the value of structural optimization.

1.3.4.2 The relationship between physiochemical properties of AMPs

As discussed above, many factors affect the activities of AMPs and some interactions exist
between these factors. In AMP design, these properties need to be considered together since
changing one of these parameters to get a desired modification of an AMP may alter other
parameters. Even a simple change in primary sequence can affect many other physicochemical
parameters which are often vital for the activity of an AMP and the range of target cells [206].
Predicting the results of an AMP modification or the function of a synthetic peptide beforehand
is still an unmet challenge. Application of molecular simulation to analyze the details of the
folding of AMP molecules and interaction with target cells [207,208] may be a promising
approach to improve current trial and error methods.
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1.3.4.3 AMP modifications
While most of AMPs are directly synthesized in their active forms, post-translational
modification of certain AMPs is necessary for their functions. Naturally forming AMPs are
processed with different post-translational modifications such as phosphorylation [209], addition
of D-amino acids [210,211], methylation [212], amidation [213], glycosylation [214], formation
of disulphide linkage [215], and proteolytic cleavage [71,216]. In some cases, these
posttranslational modifications might be important for designing new synthetic AMPs. Even
though recombinant cell systems can be used to produce these synthetic peptides with posttranslational modifications, incorporation of unnatural amino acids may require chemical
synthesis [107].

1.3.4.3.1 Modification of AMPs with covalent bonds
Covalent modification can have profound effects on the structure and function of an AMP. Even
a single disulfide bond can change the antimicrobial effect of an AMP. For example, protegrin
missing a disulphide bond becomes inactive against HSV [217]; while adding disulphide bond in
sakacin P resulted in higher antimicrobial activities [91]. In another study, a disulfide bond was
added in CP-11, a derivative of indolicidin [218], and a Trp-Trp cross-link was added in
indolicin [219]. These modified structures of indolicidins showed higher protease stability with
no change in antimicrobial activity. However increase in stability does not always lead to better
AMPs. For example, Houston et al. [220] introduced a covalent bond to form a lactam bridge
between Gln (G) and Lys (L) residues in two α-helical AMPs, e.g., cecropin and mellitin. This
modification helped AMPs to form more stable α-helix structures but decreased the antimicrobial
activity of both.
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1.3.4.3.2 Modification of AMPs by changing amino acid content
Alteration of amino acid content is one of the most studied strategies of AMP modification. Most
of these studies focus on certain amino acids since their physiological characteristics play
important roles in the activity and target spectrum of AMPs. For example proline content in the
primary sequence of an AMP has been found to affect its ability to penetrate cell membranes.
Higher proline content reduces the capability of CP26 to permeabilize E. coli cell membrane
[221]. This effect might be because of proline’s low propensity to form α-helical structures. Thus
changes in the proline content may lead to alterations of α-helical posture of an AMP.
Changing amino acid content can also affect cytotoxicity. In a study by Nell et al. [222], LL37, a
human AMP, was modified by removing neutral amino acids Asn (A) and Gln (E), and adding
more positively charged residues (two Arg (R) units) into the primary sequence. The new
synthetic peptide showed less cytotoxic effects on eukaryotic cells. This peptide was named
P60.4 and has been successfully used in nasal applications against MRSA [223]. Another
strategy to improve AMP stability is to include D-amino acids in the sequence because they are
more tolerant to proteases [224,225].

1.3.4.3.3 Modification of AMPs by amidation
With new developments in peptide synthesis, it is possible to incorporate special chemical
groups or unnatural molecules into AMPs. One of these modifications is the addition of amide
groups at the end of the peptides. In 2011, Kim et al. [226] modified PMAP-23 with amidation at
the carboxyl end and found that this derivative of PMAP-23 orients perpendicularly inside the
bacterial membrane while original PMAP-23 orients parallel to the membrane. This modification
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resulted in almost 10 fold higher cellular uptake, faster interaction with Gram-negative bacteria
cell membrane, and deeper insertion into the inner membrane than the original PMAP-23. This
carboxyl-end amidated synthetic peptide also showed better membrane-permeabilization in
liposome release tests [226]. Therefore amidation of carboxyl end has good potential to improve
the function of synthetic AMPs.
C-terminal modifications can also affect the stability of AMPs. In a previous study by Berthold
et al. [227], the C-terminal amide group of Api88 was replaced by a free acid. This modification
did not change its antimicrobial activity, but resulted in a 15 times more stable Api88 derivative
against proteases in blood serum. Replacing Arg-17 of this AMP with L-ornithine or Lhomoarginine gave 35 times higher proteolytic stability than the original Api88. However, the
latter modification decreased the antimicrobial activity by eight fold [227].

1.3.4.3.4 Modification of AMPs with unnatural amino acids
A number of studies on synthetic peptides have attempted to incorporate unnatural amino acids
into the primary sequence [146,228,229]. β-didehydrophenylalanine is an unnatural amino acids
and is used to provide better folding properties for AMPs [228]. It is widely used in medicinal
chemistry to alter the native bioactive AMPs [230]. Incorporation of β-didehydrophenylalanine
in the primary sequence of VS1 resulted in higher stability against proteases. Researchers have
also been able to introduce antifungal activities to some AMPs by incorporating undecanoic acid
and palmitic acid into their primary sequence [146,231].
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1.3.4.3.5 Modification of AMPs with computer-assisted methods
The use of computer-assisted methods in AMP research has been increasing significantly [232237]. Estimating the structure of an AMP based on its primary sequence [238], then predicting
potential mechanism of action and activity is becoming easier with the help of computational
approaches [239]. These types of artificial AMP design strategies hold potential for developing
new synthetic peptides against antibiotic-resistant superbugs [237]. Several databases about
AMPs have been created and can be accessed to compare currently available AMPs. One of the
latest AMP databases, LAMP (linking antimicrobial peptides), currently has 3904 natural and
1643 synthetic peptides [66].

1.3.4.4 New AMP design by homology modeling

Most studies about AMPs to date are inspired by natural AMPs. For example, Tossi et al. [240]
designed some synthetic peptides by identifying the common amphipathic structure of 87
different natural α-helical AMPs. These natural AMPs are composed mainly of cecropins,
magainins, brevinins, and cathelicidin peptides sourced from insects, amphibian, and mammals.
This synthetic peptide study focused on the first 20 amino acids in each sequence because the Nterminal region was shown to be necessary for antimicrobial activities [241,242]. The synthetic
peptides designed based on this strategy are able to transform into α-helical structures from
random structures with the addition of trifluoroethanol in aqueous environments. These synthetic
AMPs exhibited antimicrobial activities against Gram-positive and Gram-negative bacteria,
including some drug resistant strains. In addition, these synthetic AMPs showed low toxicity to
some eukaryotic cell lines [240].
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Designing synthetic AMPs by homology modeling within the same class might also provide a
better understanding of activity-structure relationship. Important elements from the same AMP
class may be identified using this approach to help design better molecules. Storici et al. [242]
showed that 20 residues (named PMAP-36) of an antibacterial peptide from pig bone marrow
cells are sufficient for related antibacterial activity. The AMP with these 20 residues was
chemically synthesized and showed the capability to form α-helix in the presence of
trifluoroethanol. This short synthetic peptide was found to induce permeabilization of the inner
membrane of E. coli ML35 at concentrations lower than 50 µM; while even at 100 µM it did not
cause any permeabilization to human erythrocytes [242]. In another study of homology
modeling, arenicin, protegrin, and thanatin were used as templates to generate three synthetic
peptides: AMP72, AMP126 and AMP2041. These new synthetic AMPs showed lower
cytotoxicity compared to the original AMPs and exhibited dose dependent antimicrobial
activities (0.17 to 10.12 μM) against Gram-negative bacteria [243].
It is also possible to broaden the target spectrum of an AMP by homology modeling. For
example, normally lactoferrampins are not effective against E. coli O157. A conserved sequence,
which corresponds to an α-helical region, among these AMPs was found, by aligning multiple
sequences with ClustalW analysis. This common region was modified by inserting GKLI
sequence into its primary sequence, and the new synthetic peptide showed activities against E.
coli O157 with a more stable structure compared to other lactoferrampins [244].
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1.3.5 New targets of AMPs: biofilms, persister cells, and drug resistance bacteria
Because AMPs can directly target bacterial cells, they have potential to control antibiotic tolerant
cells. Here we review some recent work on biofilms and persister cells. Biofilms are immobile
bacterial populations attached to surfaces such as human tissues and medical implants. Biofilm
formation on implant surfaces is a serious problem since every year more than $3 billion is spent
to treat implant-associated biofilm infections in the U.S. alone [245]. With cells protected by an
extracellular matrix, biofilms are highly tolerant to antimicrobials [246] and are a major cause of
chronic infections; e.g., approximately 80% of human bacterial infections are associated with
biofilms [247]. In addition to the protection by the extracellular matrix [248], biofilm associated
antibiotic resistance is also attributed to the slow growth of biofilm cells [249]. Even though
some antibiotics have been shown to effectively penetrate biofilm matrix [250], they are not
effective against these slowly growing cells, especially the dormant subpopulation known as
persister cells [251-253]. Since most AMPs target cell membrane, they may be more effective
against these dormant cells compared to antibiotics.

1.3.5.1 Biofilm control

The first obstacle of using AMPs against biofilms is the possible electrostatic interaction
between cationic peptides and negatively charged biofilm matrix [254]. Such interactions may
retard or prevent AMPs from reaching biofilm cells. Previous studies have investigated the
effects of some AMPs on biofilm inhibition and killing of bacterial cells in established biofilms.
The second type of study is especially important since treatment of mature biofilms is highly
challenging [252]. In a study by Singh et al. [255], lactoferrin was found to block biofilm
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formation of P. aeruginosa at concentrations lower than those required to kill the planktonic
cells. Also, LL-37, a human cathelicidin AMP, was shown to prevent P. aeruginosa biofilm
formation at the concentration of 0.5 µg/mL, which is below its MIC (64 µg/mL). This AMP
also showed activity against preformed (2-days old) P. aeruginosa biofilms; e.g., it reduced the
biofilm thickness by 60% and destroyed microcolony structures of the treated biofilms [256]. In
another study, a derivative of LL-37 was found effective against both Gram-positive and Gramnegative bacteria. Despite its weak antimicrobial activity against planktonic cells, this AMP
inhibited biofilm formation of P. aeruginosa, Burkholderia cenocepacia, and Listeria
monocytogenes with more than 50% reduction in biofilm mass compared to untreated controls
[257]. The same study showed that this inhibition is due to decrease in swarming and swimming
motilities, increase in twitching motility, and repression of some biofilm genes.
In addition to free AMPs, surface coating with AMPs has also been pursued since surface
modifications with AMPs might help reduce device associated infections [258-261]. Many
AMPs have been tested for their inhibitory effects on biofilm formation on implant surfaces. For
example, Tet-20, a synthetic peptide (KRWRIRVRVIRKC), tethered on an implant surface
exhibited broad antimicrobial activities both in vivo (rats) and in vitro. It is able to stop biofilm
formation and appears to be non-toxic to eukaryotic cells [258]. In another study, histatin 5 and
lactoferrin were used to coat Ti surfaces covered with an anchor peptide minTBP (RKLPDAP),
which helps binding of AMP to Ti surfaces. The conjugates of both AMPs resulted in higher
binding efficiency to Ti surfaces than AMPs alone and Porphyromonas gingivalis showed less
ATP activity and reduced biofilm formation on coated surfaces [262].
In addition to naturally existing AMPs, some synthetic AMPs were also used to treat biofilms. A
synthetic histatin analogue dhvar4 was tested against oral flora on hydroxyapatite disks and this
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AMP reduced the number of viable biofilm cells by 1.5 log compared to the control [263].
MUC7, a native saliva AMP from humans, and its modified forms, MUC17 12-mer-L and 20mer, showed inhibitory effects on S. mutans biofilm formation [264]. In another study, a
derivative of LL-37 which is an AMP from human innate immune system, cleared P. sinusitis
biofilms in vivo (New Zealand rabbits). However, it also led to some toxicity and
proinflammation in the sinuses [265].
As discussed above, the extracellular matrix of a biofilm is thought to form a diffusion barrier
against certain AMPs [246]. It is known that this negatively charged barrier protects the cells
inside from positively charged antimicrobial agents and the alginate in biofilm matrix can reduce
the diffusion of antimicrobial agents [266]. Thus, it is important to obtain AMPs that can diffuse
into biofilms and kill biofilm cells. Recently a synthetic peptide, (RW)4D dendrimer [267] was
demonstrated to inhibit planktonic growth and biofilm formation of E. coli dose dependently.
This AMP inhibited biofilm formation by 93.5% at 40 µM. This dendrimer did not detach
preformed biofilms, but was able to kill most of the cells residing in mature biofilms dose
dependently [268]. Later, (RW)n-NH2 based AMPs with different chain length (where n = 2, 3,
and 4) were compared for their effects on E. coli RP437 biofilms. The chain length was found to
be important to the activity of these peptides. Longer peptides, (RW)3-NH2 and (RW)4-NH2,
showed significant inhibition of planktonic growth (36% reduction in growth rate) while a
shorter peptides (RW)2-NH2 did not cause a clear inhibition at concentrations up to 200 µM. This
length-activity relation was also found for biofilm inhibition. E. coli biofilm surface coverage
and the viability of biofilm cells were reduced significantly by the longer peptides (95%
inhibition of biofilm growth by 200 µM (RW)3-NH2 and 84.4% inhibition of biofilm growth by
200 µM (RW)4-NH2). Preformed biofilms were also tested with these peptides. However, the
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treatment of preformed biofilms with these peptides did not show the same length-activity
relationship. Interestingly, 200 µM (RW)3-NH2 showed significant killing of biofilm cells while
200 µM (RW)4-NH2 showed strong biofilm dispersion (91.5% reduction in biofilm surface
coverage at 200 µM) with no apparent killing effect on biofilm cells. Although 200 µM (RW)4NH2 did not kill biofilm cells directly, the detached biofilm cells were killed by this peptide
effectively [269].
AMPs have also been tested against the biofilms of drug resistant bacteria. In a study by Okuda
et al. [270], nisin A and lacticin Q were tested against mature biofilms of a MRSA strain, S.
aureus MR23. Nisin A at 40 µM was found to kill more than 95% biofilm cells while lacticin Q
at 80 µM killed around 90% of the biofilm cells. In another study, GL13K derived from human
parotid secretory protein (PSP) killed 99.9% of 24 hour biofilm cells of P. aeruginosa when it
was added at 100 µg/mL for a two hour treatment [271].
NRC-16, a synthetic peptide, was tested against biofilm formation of three P. aeruginosa strains
and compared with antibiotics such as ampicillin, chloramphenicol, and ciprofloxacin. NRC-16
showed biofilm inhibition at 8 µg/mL, which is 64 fold less than the antibiotic concentrations
required to kill these P. aeruginosa strains [272].
There are also some AMPs that can sensitize biofilm cells to other antimicrobial agents. For
example, lactoferrin does not kill S. epidermidis or affect its growth. However treatment of S.
epidermidis biofilms on contact lenses with lactoferrin and vancomycin together showed a 2 fold
decrease in both MBC (minimal bactericidal concentration) and MIC of biofilm cells compared
to the treatment with vancomycin alone [273].
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1.3.5.2 Persister control
Persister cells can be found in almost any microbial populations [19]. However, membrane
integrity is essential for the survival of bacteria irrespective of the metabolic stage of the cell and
cell membrane is a major target of AMPs. Thus, AMPs may have good potential to kill persister
cells. In a recent study, a synthetic cationic peptide, (RW)4-NH2, was found to kill more than
99% of E. coli HM22 persister cells in planktonic culture. Besides, this synthetic peptide reduced
the number of persister cells in mature biofilms by up to 98% at 40 µM. More interestingly, the
combination of this peptide with oflaxacin (5 µg/mL) resulted in complete eradication of viable
cells in E. coli HM22 biofilms including persister cells [274]. Thus, the combination of
conventional antibiotics with AMPs may offer a synergy to control drug tolerant infections.

1.3.6 Resistance to antimicrobial peptides
There are mainly two different types of resistance mechanisms against AMPs: constitutive
resistance and inducible resistance [275]. The inducible resistance mechanisms include substitution
[276], modification [277], and acylation [278] of the membrane molecules, activation of some
proteolytic enzymes [279] and efflux pumps [280], and modifications of intracellular targets [281].
The constitutive resistance mechanisms include electrostatic shielding [282], changes in
membrane potential during different stages of cell growth [283], and biofilm formation [275].
These resistance mechanisms are illustrated in Figure 1-4.
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Figure 1-4. Schematic representation of AMP resistance mechanisms. (A) Gram-positive
bacteria resist AMPs via teichoic acid modification of LPS molecules and L-lysine modification
of phospholipids. (B) Gram-negative bacteria resist AMPs by modifying LPS molecules with
aminoarabinose or acylation of Lipid A unit of LPS molecules. (C) Bacteria express some
positively charged proteins and integrate them in the membrane so positive charges repulse each
other and bacteria can resist such AMPs. (D) Bacteria produce negatively charged proteins and
secrete them into extracellular environment to bind and block AMPs. (E) The intracellular AMPs
are extruded by efflux pumps. (F) The AMPs inside the cell are degraded by proteases.
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For example the activity of some AMPs against S. aureus can be inhibited by adhesin molecules
on the cell surface of this bacterium. These adhesin molecules are polymeric substances and stay
on the cell surface after secretion [284]. Since adhesin is a positively charged polymer, it can
form a repulsive barrier against positively charged AMPs. Salmonella typhimurium also has a
membrane bound lipid A modification system, which defends themselves against AMPs from the
host [285]. In this system, PhoQ is a membrane bound sensor kinase and PhoP is intracellular
response regulator. PhoQ is activated in the presence of high level positive charges outside the
cells. It then phosphorylates the PhoP causing up-regulation of some genes including those
related to AMP resistance. This system is not active when the extracellular level of Ca2+, Mg2+,
or Mn2+ ions is low since divalent cations interact with PhoQ and change its conformation [110].
Although bacteria have diverse mechanisms for resistance to AMPs, it is encouraging to notice
that the general lipid bilayer structure of bacterial membranes makes it hard to develop a
complete resistance against AMPs. Also, the resistance against AMPs reported to date is not as
strong as those against antibiotics and it only covers a limited number of AMPs.

1.4 Outlook
The urgent need to obtain new antimicrobials has been driving AMP research. With rapid growth
in related knowledge and lead compounds, more AMPs may enter clinical tests and treatment in
the near feature. However, infection control by AMP is still hindered by several challenges
including low specificity, high manufacturer cost, potential toxicity to animal cells, and lack of a
robust guideline for rational design.
As we have seen from synthetic and modified AMP studies, it is easy to change characteristics of
an AMP with even small modifications. However, predicting the results of these changes is still
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challenging. Thus, there is a need to understand the effects of structural modifications on the
physiochemical characteristics of AMPs as well as their target spectrum and activity. Recently,
these types of studies have been increasing and computational approaches have been involved in
AMP research. These efforts will help to better understand the mode of action of AMPs and
predict their activities.
Another understudied area is using AMPs to control antibiotic resistant bacteria, biofilms, and
persister cells. These targets are highly resistant to traditional antibiotics and play important roles
in infections. Since AMPs target cell membrane, they have good potential in such applications.
On the other hand, because AMPs have not been well studied for biofilm and persister control,
there might be some existing natural AMPs that are effective against these targets with potential
synergy with antibiotics. Applying AMPs with biofilm matrix degrading enzymes might also be
a good strategy to eliminate biofilms. Further development in this area and AMP research in
general will benefit from close collaboration of different disciplines and new tools that can
decipher the structure-function relationship and more efficiently synthesize and modify AMP
molecules.
To gain better fundamental understanding of the characteristics and antimicrobial activities of
AMPs we have tailored different design approaches to develop better AMPs. Among these
approaches, a dendrimeric peptide with repetitive functional groups on a branched core (2D-24,
Chapter 2), a triazine derivative (TN-5, Chapter 3), which is a relatively new source for
antimicrobial agent design, and a native human originated AMP with its neutral charged
derivative (calcitermin, Chapter 5) were studied. The majority of AMPs targets cell membrane,
disrupting its integrity and causing membrane depolarization. Having antimicrobial agents active
on cell membrane holds a great potential with low risk for bacterial resistance since membrane
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structure is present in all microorganisms and changing the content or structure of this lipid
bilayer can be lethal to bacteria. To better understand the membrane function and antimicrobial
susceptibility, a new strategy to target cell membrane of persister cells was also evaluated with
the antibiotic erythromycin (Chapter 4), which is the substrate of efflux pump AcrAB.
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CHAPTER 2

SYNTHETIC DENDRIMERIC PEPTIDE ACTIVE AGAINST BIOFILM AND
PERSISTER CELLS OF PSEUDOMONAS AERUGINOSA

This chapter has been published as below with minor modifications. Ali Adem Bahar, Zhigang
Liu, Filbert Totsingan, Carlos Buitrago, Neville Kallenbach, Dacheng Ren. Synthetic
dendrimeric peptide active against biofilm and persister cells of Pseudomonas aeruginosa.
Applied Microbiology and Biotechnology 2015, 99, 8125-8135.
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2.1 Abstract
Antimicrobial dendrimeric peptides (AMDP) are a relatively new class of agents displaying
repetitive functional groups on a branched core. Previous work done by Liu et al. in 2007 has
investigated the length requirement for antimicrobial activity of peptides consisting of repeated
arginine (R) and tryptophan (W) side chains and found that even short linear RW repeats are
active, providing a starting point for a de novo design of multivalent structures. In this study, we
tested a new synthetic dendrimer, 2D-24, for its antimicrobial activity against Pseudomonas
aeruginosa, including the wild-type PAO1 and its mucoid mutant PDO300. This synthetic
AMDP was found to kill planktonic cells of both PAO1 and PDO300 in a dose-dependent
manner, with nearly complete killing of both strains observed when treated with 50 μM of this
agent. In addition to planktonic cells, 2D-24 was also found to kill biofilm cells of both strains in
a dose-dependent manner. For example, treatment with 30 μM 2D-24 led to 94.4 ± 1.4 and
93.9 ± 4.2 % killing of PAO1 and PDO300 biofilm cells, respectively. Furthermore, 2D-24 was
effective in killing multidrug-tolerant persister cells of PAO1 and PDO300. While higher
concentrations of 2D-24 were required to kill persister cells, combinations of 2D-24 with
ciprofloxacin, tobramycin, or carbenicillin showed synergistic effects on killing persister cells of
both strains. Based on hemolysis assays using a co-culture model of PAO1 and human epithelial
cells, 2D-24 was found to kill P. aeruginosa cells at concentrations that are not toxic to
mammalian cells.
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2.2 Introduction
Bacteria have evolved diverse mechanisms to survive from the attack of antibiotics. One such
mechanism involves persister cell formation, by which a small population in a bacterial culture
enters an inactive stage and exhibits high tolerance to antibiotics and other forms of stress [1].
Consistently, persister cell formation has been implicated in chronic infections by
Mycobacterium tuberculosis and Pseudomonas aeruginosa [2,3].
In addition to persister formation, bacteria can also evade antibiotics by forming multicellular
structures, known as biofilms, in which bacterial cells adhere to a surface and secrete an
extracellular matrix that protects them from environmental stresses [4]. Due to limited mass
transfer [5], biofilm cells grow slowly with reduced metabolism and exhibit high tolerance to
antimicrobial agents [6,7]. It is estimated that 80 % of bacterial infections in humans involve
biofilms [8]. Thus, biofilms present a serious complication associated with chronic infections
especially in patients with compromised immune systems [9-12].
To address the challenge of drug-resistant infections, it is important to develop new
antimicrobials that are effective against biofilms and persister cells. Antimicrobial peptides
(AMP) are promising alternative antibiotics due to their rapid killing effects, low frequency of
resistance development, and broad spectrum of target microbes [13]. Thousands of AMPs have
been identified to date [14], and many synthetic analogs have been developed and tested against
infectious microorganisms including protozoa, fungi, bacteria, and viruses [15-19]. However,
most AMPs are not appropriate for therapeutic use due to cytotoxicity, high MIC (minimum
inhibitory concentration) values, in vivo inactivation by proteases, and/or high production cost
[20]. Therefore, it is important to develop new AMPs to overcome these challenges. One such
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strategy is to modify the AMP molecules by amidation of carboxyl ends [21], cyclization,
covalent modification with disulfide bonds [22], and/or alteration of amino acid content such as
adding prolines [23]. Modifications of this kind can affect critical physiochemical properties of
natural AMPs and thus the target spectrum, cytotoxicity to eukaryotic cells, antimicrobial
activity, and stability against proteases [13].
Antimicrobial dendrimeric peptides (AMDP) are a relatively new class of AMPs with repeating
functional groups linked to a multivalent scaffold. The Kallenbach group has investigated the
length requirement for antimicrobial activity of peptides only consisting of amino acid arginine
(R) and tryptophan (W) repeats. Even short repeats of RW (trimers, for example) are active,
providing a starting point for a de novo design of minimal structures [24]. Further studies found
that dendrimeric displays of di- or tripeptides of arginine and tryptophan can render the AMPs
more potent and less cytotoxic than natural AMPs [25]. Recently, the Ren lab showed that some
synthetic AMPs with RW repeats are effective against planktonic and biofilm cells of
Escherichia coli [26,27] including persister cells [28]. To further evaluate the potential of
AMDPs as more effective antibacterial agents, the agent 2D-24, containing RWR and RTtbR(2)
tripeptide branches (Fig. 2-1), was tested in this study for its antimicrobial activities against
planktonic, biofilm, and persister cells of the wild-type P. aeruginosa PAO1 and its mucoid
mutant PDO300.
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Figure 2-1. Structure of 2D-24
P. aeruginosa is a Gram-negative bacterium with exceptional capabilities to adapt to different
living environments [29]. It is a well-known opportunistic human pathogen [30], causing serious
infections in patients with comprised immunity or with cystic fibrosis [31,32]. P. aeruginosa can
acquire antibiotic tolerance through biofilm and persister formation [33,34]. In addition, during
chronic colonization in the lungs of cystic fibrosis patients, P. aeruginosa commonly acquires
mutations that lead to a mucoid phenotype overproducing the polysaccharide alginate and
therefore acquires a higher-level antibiotic tolerance [35-37]. With its strong clinical relevance,
P. aeruginosa is a good model bacterium for studying antibiotic resistance and for testing new
antimicrobials.
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2.3 Materials and methods

2.3.1 2D-24 Synthesis

The synthesis of 2D-24 (50-μmol scale) was performed in the lab of Kallenbach at New York
University.

2.3.2 Bacterial strain and growth media.
P. aeruginosa PAO1 (ATCC BAA-47, henceforth PAO1) and P. aeruginosa PDO300 (mucA22
mutant of P. aeruginosa PAO1, constructed based on a clinical isolate of P. aeruginosa FRD1
from cystic fibrosis patient [38]; henceforth, PDO300 [39]) were routinely cultured in Lysogeny
broth (LB) medium [40] containing 10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl at
37°C with shaking at 200 rpm. To minimize the difference in persistence between overnight
cultures by freeze and thaw, all overnight cultures were inoculated with single-use glycerol
stocks prepared from the same overnight culture of desired bacteria.

2.3.3 Effects of 2D-24 on planktonic cells

Exponential cultures were prepared by inoculating 3 mL LB medium with an overnight culture to
an optical density at 600 nm (OD600) of 0.01 and incubated at 37°C with 200 rpm shaking until
OD600 reached 0.5. Then, different concentrations of 2D-24 were added. The control and treated
samples were incubated for 3 h at 37°C with 200 rpm shaking. Then, the cells were washed three
times with phosphate buffered saline (PBS, pH 7.4). The viability of each sample was
determined by counting colony-forming units (CFUs) using a drop-plate method as described
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previously [28]. Briefly, each sample was diluted in a 10× series with 0.85 % NaCl solution. The
CFU was determined by loading 10 μL of each diluted sample on a LB agar plate and counting
the CFUs after incubation at 37°C overnight.

2.3.4 Effect of 2D-24 on biofilms
For each treatment, three separate polished (using 1000 grit sand paper, 3 M, St. Paul, MN,
USA) sterile 2 cm × 1 cm 316-L stainless steel coupons were placed in a petri dish containing
20 mL LB medium. To initiate biofilm formation, the medium was inoculated with an overnight
culture to OD600 of 0.01. These coupons were incubated for 24 h at 37°C without shaking. The
coupons were then washed gently with PBS three times and placed in a 12-well plate (one
coupon in each well) with 2 mL PBS in each well and 2D-24 supplemented at concentrations of
0.1 to 30 μM. After incubation for 3.5 h, biofilm coupons were washed with PBS and transferred
to 15-mL sterile conical tubes with 3 mL PBS buffer in each. The samples were gently sonicated
for 4 min in a sonication bath (Branson B200 Ultrasonic, Danbury, CT, USA) and vortexed for
15 s (this condition was confirmed not to kill the cells; data not shown). The cells, thus detached
from coupons, were plated using the drop-plate method [28] to determine the CFUs.

2.3.5 Persister isolation and killing by 2D-24
Persister cells of PAO1 and PDO300 were isolated by killing normal cells in overnight cultures
with 200 μg/mL ciprofloxacin (Cip) for 3.5 h at 37°C, as described previously [41,42]. Longer
treatment, 6.5 h, was also tested to confirm the treatment time was sufficient (no additional
killing with extended time) as described in (Pan et al. 2012). After antibiotic treatment, surviving
persister cells were washed twice with PBS buffer to remove any remaining antibiotic. The
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collected cells were resuspended in 3 mL PBS supplemented with 2D-24 at different
concentrations and incubated for 3.5 h at 37°C with 200 rpm shaking. After treatment, the cells
were washed with PBS and plated to determine the viability by counting CFU as described
above.

2.3.6 Fluorescence microscopy
To corroborate the CFU results, the LIVE/DEAD BacLight™ bacterial viability kit (Life
Technologies Inc., Carlsbad, CA, USA) was used to determine the viability of biofilm cells of
PAO1 and PDO300 on 316-L stainless steel coupons. The 24-h P. aeruginosa biofilms grown on
these surfaces were washed gently with 0.85 % NaCl (w/v) solution three times to remove
planktonic cells. Then, 1 μL of 20 mM propidium iodide and 1 μL of 3.34 mM SYTO 9 stains
were added in 1 mL PBS to stain each biofilm sample for 10 min in the dark. The stained biofilm
samples were examined with an Axio Imager M1 fluorescence microscope (Carl Zeiss Inc.,
Berlin, Germany). At least five randomly selected spots were examined for each sample.

2.3.7 Synergistic effects between 2D-24 and antibiotics
Three different antibiotics were tested including Cip (a fluoroquinolone targeting DNA gyrase)
[43], tobramycin (Tob, an aminoglycoside targeting translation by binding to ribosome subunits)
[44], and carbenicillin (Car, a carboxypenicillin targeting bacterial cell wall synthesis) [45].
Normal and persister cells of PAO1 and PDO300 were treated with antibiotic alone, 2D-24
alone, or a combination of an antibiotic and 2D-24 to assess any synergistic effects in bacterial
killing. The viability of bacterial cells was determined using the drop-plate method as described
above.
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2.3.8 Cytotoxicity and antimicrobial effects in co-cultures

The cytotoxicity of 2D-24 on eukaryotic cells was evaluated using IB3-1 cells and
LIVE/DEAD® viability/cytotoxicity kit (Invitrogen, NY, USA). IB3-1 cells were grown in
LHC-8 basal medium (Invitrogen, NY, USA) supplemented with 10 % (v/v) fetal bovine serum
(FBS) in flasks pre-coated with 100 μg/mL bovine serum albumin (BSA) and 30 μg/mL collagen
at 37°C with 5 % CO2. All treatments were performed in antibiotic-free medium. To test the
cytotoxicity, IB3-1 [46] (a compound heterozygote bronchial epithelial cell line from a CF
patient) cells were seeded into black-sided clear-bottom 96-well plates (5 × 104 cells per well)
and incubated until the cell density reached 1 × 106 cells per well. Then, 2D-24 was added at
concentrations of 1 to 32 μM. After treatment for 24 h, EthD-1 and calcein AM were used to
assess the viability of IB3-1 cells. The optimal concentrations of EthD-1 (1 μM) and calcein AM
(2 μM) were determined prior to the treatments to label live and dead IB3-1 cells distinctively.
After staining for 30 min at 37°C, samples were washed with PBS and analyzed using a
fluorescence microplate reader (model FLx800, Bio-Tek Instruments, Winooski, VT, USA). To
test the effects of 2D-24 on PAO1 in co-cultures, PAO1 cells (4 × 106 cells/mL) were added
either with 2D-24 together or at 4 h prior to 2D-24 treatment (20 h after the inoculation of IB3-1
cells). The viability of IB3-1 cells was determined as described above. To compare the effects on
bacteria, PAO1 cells were treated in the same medium (LHC-8 basal medium) but in the absence
of IB3-1 cells. The viability of PAO1 cells was determined by counting CFU using the dropplate method as described above. All treatments were tested in triplicate.
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2.3.9 Statistical analysis
The data from CFU experiments were analyzed with one-way ANOVA followed by Tukey test
using SAS version 9.3 (SAS Institute, Cary, NC, USA). Differences with p < 0.05 were
considered to be statistically significant.

2.4 Results

2.4.1 Antimicrobial effects of 2D-24 on planktonic cells

First, the effects of 2D-24 on normal planktonic cells were evaluated by treating cells in
exponential phase cultures with different concentrations of 2D-24. As shown in Fig. 2-2, 2D-24
was effective in killing both PAO1 and PDO300 planktonic cells in a dose-dependent manner.
For example, 5 μM 2D-24 was found to kill 53.3 ± 3.3 % PAO1 (p < 0.001) and 40.3 ± 6.2 %
PDO300 (p < 0.005) cells, respectively. The killing efficiency increased with the concentration
of 2D-24. At 20 μM, 79.9 ± 4.7 % (p < 0.001) and 84.6 ± 7.1 % (p < 0.001) killing was obtained
for PAO1 and PDO300, respectively. No viable cells of either strain were found after treatment
with 50 μM 2D-24, suggesting that complete killing is possible. Interestingly, while the mucoid
strain PDO300 is more tolerant to antibiotics than the wild-type PAO1 [37], 2D-24 exhibited
similar activities in killing PAO1 and PDO300.
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Figure 2-2. Effects of 2D-24 on planktonic cells of PAO1 (A) and PDO300 (B). The dendrimer
2D-24 was added at different concentrations to exponential cultures, and the viability was
determined by counting CFUs

2.4.2 Antimicrobial effects of 2D-24 on biofilm cells
In addition to planktonic cells, 2D-24 was also found to kill PAO1 and PDO300 biofilm cells
effectively (Fig. 2-3). At 5 μM, 2D-24 is slightly more effective against PAO1 than PDO300.
For example, 2D-24 exhibited 55.8 ± 6.5 % killing (p < 0.001) of PAO1 biofilm cells, while the
killing of PDO300 biofilm cells with the same concentration of 2D-24 was 31.6 ± 8.8 %
(p < 0.05). The activity increased with 2D-24 concentration for both strains, e.g., 2D-24 killed
87.8 ± 3.1 % (p < 0.001) and 94.4 ± 1.4 % (p < 0.001) of PAO1 biofilm cells when treated at 20
and 30 μM, respectively. Similar activities against PDO300 biofilms were observed, e.g., 2D-24
exhibited 81.7 ± 3.5 and 93.9 ± 4.2 % killing of PDO300 biofilm cells when added at 20 and
30 μM, respectively (p < 0.001 for both). Since the mucoid strain PDO300 is tolerant to multiple
antibiotics [47,48], the finding that 2D-24 is equally effective in killing PAO1 and PDO300
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biofilms is encouraging. The effective killing of biofilm cells, especially those of PDO300,
suggests that 2D-24 is able to penetrate the biofilm matrix and the alginate layer of the mucoid
strain.

Figure 2-3. Effects of 2D-24 on PAO1 (A) and PDO300 (B) biofilm cells. The biofilms were
cultured for 24 h in LB medium before treatment with 2D-24 for 3.5 h in PBS

2.4.3 LIVE/DEAD staining of biofilms
To corroborate the CFU results of biofilm killing, the control and 2D-24-treated biofilm samples
were analyzed using LIVE/DEAD staining. Consistent with CFU data, the LIVE/DEAD images
also showed dose-dependent killing of biofilms cells by 2D-24. While the cells in untreated
control were healthy (green), killing was observed (red) with addition of 2D-24 and the effects
were dose dependent (Fig. 2-4).
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Figure 2-4. LIVE/DEAD images of PAO1 and PDO300 biofilms. A, B, C: PAO1 biofilms
treated with 0, 10, and 30 μM 2D-24, respectively. D, E, F: PDO300 biofilms treated with 0, 10,
and 30 μM 2D-24, respectively. Bar = 10 μm
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2.4.4. Antimicrobial effects of 2D-24 on persister cells
Because persister cells are highly tolerant to antibiotics [49], we were motivated to also test 2D24 against persister cells of PAO1 and PDO300 (Fig. 2-5). It was found that 2D-24 is effective in
killing persister cells of both strains, although higher concentrations of 2D-24 than those required
to kill normal cells are needed. For example, 200 μM of 2D-24 killed 68.7 ± 6.7 % (p < 0.001) of
PAO1 and 89.0 ± 3.2 % (p < 0.001) of PDO300 persister cells. At concentrations below 50 μM,
2D-24 exhibited a stronger killing effect on PAO1 persister cells compared to PDO300. For
example, at 30 μM, 2D-24 showed 30.3 ± 6.1 % (p < 0.05) killing of PAO1 persister cells, while
the same condition did not show any significant killing (p = 0.08) of PDO300 persister cells.
Interestingly, there was a sharp increase in the susceptibility of PDO300 persister cells between
30 and 50 μM of 2D-24; the killing increased from 10.71 ± 6.2 to 87.6 ± 3.3 % (p < 0.05) when
2D-24 was added at 30 and 50 μM, respectively. These results suggest that a threshold may exist
for the activity of 2D-24 to kill PDO300 persister cells effectively.

Figure 2-5. Effects of 2D-24 on persister cells of PAO1 (A) and PDO300 (B). Persister cells
were isolated by killing normal cells in overnight cultures with 200 μg/mL Cip for 3.5 h
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2.4.5 Synergistic effects between 2D-24 and antibiotics
Since some membrane-active AMPs can synergize with traditional antibiotics in bacterial killing
[50], we also tested if the activity of 2D-24 can be enhanced through synergy with antibiotics. To
achieve this, 1 μg/mL Cip, 1.5 μg/mL Tob, and 0.75 μg/mL Car (which can kill ~0.5 log of
normal planktonic cells) were tested in the presence and absence of 2D-24. As shown in
Figure 2-6, treatment with 1.5 μg/mL Tob or 5 μM 2D-24 alone killed 0.4 log (59.2 ± 0.7 %) and
0.3 log (54.1 ± 1.7 %) of normal planktonic PAO1 cells, respectively. In comparison, cotreatment with both agents caused 2.3 logs of killing (99.6 ± 0.6 %). Similar results were
obtained for Cip and Car. Thus, there is indeed a synergy between 2D-24 and these three
antibiotics. Co-treatments of normal planktonic cells of PDO300 with antibiotics and 2D-24 gave
similar results. Thus, 2D-24 and the tested antibiotics show synergy in killing both strains.

Figure 2-6. Co-treatment of planktonic PAO1 (A) and PDO300 (B) cells with 2D-24 and
antibiotics. Cip, Tob, and Car antibiotics were tested on exponential cultures (OD600 = 0.5).
Antibiotics or 2D-24 alone were used as controls
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Previously, we reported that some membrane-active AMPs, containing tryptophan and arginine
repeats, synergize with ampicillin in killing E. coli persister cells [28]. Thus, we tested if there is
also a synergy in killing persister cells with 2D-24 and antibiotics. The results showed that there
are synergies in killing persister cells, especially the co-treatment with 2D-24 and Tob (Fig. 2-7).
For example, Tob (100 μg/mL) or 2D-24 (30 μM) alone killed <1.5 % and 0.1 log (20.7 ± 1.4 %)
of PAO1 persister cells, respectively. In comparison, co-treatment with these two agents led to
0.58 log (73.8 ± 3.8 %) killing of persister cells. Similar results were obtained for PDO300
persister cells.

Figure 2-7. Co-treatment of PAO1(A) and PDO300 (B) persister cells with 2D-24 and
antibiotics. Cip, Tob, and Car antibiotics were tested in the presence and absence of 30 μM 2D24. The persister cells were isolated from overnight cultures by killing normal cells with
200 μg/mL Cip for 3.5 h. Antibiotics were tested at different concentrations (1–1000 μg/mL
tested), but only the results of 100 μg/mL are shown. The CFU data of untreated controls in each
run were normalized as 100 % for the convenience of data comparison across the samples
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2.4.6 Cytotoxicity of 2D-24 on IB3-1 lung epithelial cell line in a co-culture with PAO1
It is encouraging to find that 2D-24 is effective against the biofilm and persister cells of P.
aeruginosa. To determine if 2D-24 is safe to mammalian cells at the effective concentrations, we
further tested the cytotoxicity of 2D-24 on the IB3-1 lung epithelial cell line. The results showed
that 2D-24 is not toxic to IB3-1 cells at concentrations up to 32 μM after treatment for 24 h
(Fig. 2-8), e.g., no significant change in viability was found compared to the 2D-24-free control
(p = 0.28). In comparison, when PAO1 cells were treated by 2D-24 at the same concentration in
the same medium, significant killing was observed. For example, 84.9 ± 9.5 % of PAO1 cells
were killed by 16 μM 2D-24. Consistently, 2D-24 was found to protect IB3-1 epithelial cells
from the infection of PAO1 in a co-culture model. In the absence of 2D-24, only 45.7 ± 2.6 % of
IB3-1 cells remained viable after 24 h incubation with PAO1. In comparison, the presence of
2D-24 increased the viability of IB3-1 cells in a concentration-dependent manner. For example,
94.7 ± 2.7 and 82.6 ± 5.2 % of IB3-1 cells remained viable when 16 μM 2D-24 was added along
with the inoculation of PAO1 and at 4 h after inoculation, respectively.
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Figure 2-8. Cytotoxicity of 2D-24 on IB3-1 cells and the effects in a co-culture model. Different
2D-24 concentrations, from 1 to 32 μM, were tested on IB3-1 cells alone (circles), added
together with PAO1 inoculation (squares), or 4 h after PAO1 inoculation (triangles). Besides,
PAO1 cells alone in LHC-8 medium with no IB3-1 cells (crossings) were treated with the same
concentrations of 2D-24 to evaluate bacterial killing. The viability of IB3-1 cells was determined
using the LIVE/DEAD staining kit by following the manufacturer’s protocol. The viability of
PAO1 was determined by counting CFUs

2.5 Discussion
Although more than 5000 AMPs have been identified to date [51], most previous studies of their
activities have focused on activities against normal planktonic bacterial cells [13]. In
comparison, the effects of AMPs on biofilm cells have been less studied, and few reports exist
regarding their effects on persister cells. In this study, a new synthetic AMDP, 2D-24, was tested
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against planktonic and biofilm cells, including persister cells of P. aeruginosa PAO1 and
PDO300. Significant killing effects were observed for all the cell types tested.
Most synthetic AMPs are designed based on the characteristics of natural AMPs. In general, they
are positively charged, amphiphilic molecules [52,53] and act on negatively charged cell walls
and membranes, impairing the membrane potential and leading to cell death [13]. AMPs have a
wide spectrum of target microbes. It has been postulated that the effectiveness of AMPs on
bacteria depends on the peptide/lipid ratio during treatment [54]. In this study, the killing of
PDO300 persister cells increased drastically when the concentration of 2D-24 reached 30 μM,
which indicates that the killing may be dependent on peptide/lipid ratio as well. However, the
biofilm and normal planktonic cells of PDO300 and all types of PAO1 cells tested here did not
show a threshold concentration of 2D-24 for killing. It will be helpful to further investigate if
persister formation affects the interaction between 2D-24 and the cell membrane of this mucoid
strain.
Biofilms are composed of bacterial populations that include cells at different stages embedded in
a complex extracellular matrix [55]; cells in biofilms can be up to 1000 times more tolerant to
antibiotics than their planktonic counterparts [56]. Intriguingly, 2D-24 appeared to be equally
effective against normal planktonic cells and biofilm cells of PAO1 and PDO300. This finding
suggests that 2D-24 can penetrate biofilm matrix and is effective in killing biofilm cells. In
comparison, persister cells tolerated higher concentrations of 2D-24. Overall, concentrations
higher than 20 μM of 2D-24 were found sufficient to kill more than 80 % of both planktonic and
biofilm cells of PAO1 and PDO300, while concentrations higher than 50 μM are required to
achieve a similar level of killing of persister cells of these strains. Interestingly, when treated
with higher concentrations of 2D-24, persister cells of PDO300 were slightly more susceptible
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than PAO1 persister cells. For example, 50 and 200 μM 2D-24 exhibited 19.8 and 57.3 % more
killing of PDO300 persister cells compared to PAO1, respectively.
Mucoid conversion with overproduction of alginate is thought to play an important role in
chronic infections by P. aeruginosa [57] since mucoid strains are generally more tolerant to
antibiotics than the wild-type strain [47,48]. It is interesting that the killing effects of 2D-24 on
biofilm cells of PDO300 and PAO1 were similar. This suggests that 2D-24 is able to penetrate
alginate and interact with PDO300 cellular targets.
Besides the killing of P. aeruginosa cells by 2D-24 alone, intriguing synergistic effects were
observed when the cells were treated with 2D-24 and Cip, Tob, or Car, which are antibiotics
targeting DNA, protein, and cell wall synthesis, respectively. Similar synergistic effects were
observed for killing both PAO1 and PDO300 normal planktonic and persister cells (Figs. 2-6 and
2-7). Among these antibiotics, the strongest synergy was observed for Tob, while Cip exhibited
lower synergy. This is probably because the persister cells had been exposed to Cip during
persister isolation. The mechanism of synergistic killing of bacteria by 2D-24 and antibiotics is
unknown. Most AMPs target cell membrane and thus alter the membrane potential [13]. We
speculate that membrane disruption, depolarization, or permeabilization by 2D-24 can lead to
reduced membrane potential along with lower energy production. This may favor the penetration
of cell membrane by some antibiotics, which is consistent with a recent study by Schmidt et al.
[58] showing a peptide-tobramycin conjugate -Pentobra- can effectively enter the cells of P.
aeruginosa, E. coli, and Staphylococcus aureus. The peptide domain of this molecule is rich in
arginine and tryptophan residues (RQIKIWFQNRRW), similar to the amino acid content of 2D24.
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We speculate that the increase in intracellular antibiotic concentration along with membrane
damage by 2D-24 may render the persister cells unable to wake up, leading to cell death.
Alternatively, it may also be possible that the stress response to 2D-24 treatment could activate
certain cellular activities targeted by antibiotics and thus increase the antibiotic susceptibility of
persister cells. It will be interesting to test the effects of 2D-24 on the integrity of treated cells
and compare the penetration of antibiotics through cell membrane in the presence and absence of
2D-24.
It is generally appreciated that AMPs and analogs can have more than one inactivating target in
bacteria. Even though persister cells are known to be latent and different from normal active
cells, they still need to maintain intact cell membrane structures. While the cell surface and
membrane are generally implicated in the antibacterial action by AMPs, we still lack a complete
understanding of the detailed mechanism(s) involved. Similar to bactericidal antibiotics, we
recently reported that a different AMDP analog, (RW)4D, generates hydroxide radicals in target
bacterial cells via a Fenton reaction [59]. It will be interesting to study the interaction of 2D-24
with cellular targets among regular planktonic, persister, and biofilm cells of P. aeruginosa.
In addition, we obtained data showing that 2D-24 is effective in killing P. aeruginosa at
concentrations not toxic to IB3-1 epithelial cells. Similar to the uninfected control, the viability
of IB3-1 cells increased to near 90 % when 2D-24 is added into the culture medium together
with PAO1 at inoculation. This finding is intriguing since cytotoxicity is a major challenge in
bacterial control with AMPs. Further in vivo tests will help evaluate the clinical potential of this
new dendrimer.
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In summary, a new antimicrobial dendrimer 2D-24 was tested for its effects on the biofilm and
planktonic cells (including persister cells) of PAO1 and its mucoid mutant PDO300. Similar
killing activities were observed for regular planktonic and biofilm cells of both strains, and this
agent was also found to kill persister cells of both strains. Synergy between 2D-24 and
antibiotics in killing P. aeruginosa was also observed. Further testing using co-cultures of PAO1
and human IB3-1 cells demonstrated that 2D-24 is effective against bacteria at concentrations
nontoxic to mammalian cells. Thus, our in vitro data provide encouraging evidence for potential
application of 2D-24 in treatment of chronic infections caused by P. aeruginosa. In addition to
the investigation of mechanistic aspects of 2D-24 action, animal studies will be needed to
demonstrate its efficacy in vivo.
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CHAPTER 3

CONTROLLING PERSISTER AND BIOFILM CELLS OF GRAM-NEGATIVE
BACTERIA WITH A NEW 1,3,5-TRIAZINE DERIVATIVE

This chapter has been published as below with minor modifications. Ali Adem Bahar, Zhigang
Liu, Meagan Garafalo, Neville Kallenbach and Dacheng Ren. Controlling Persister and Biofilm
Cells of Gram-Negative Bacteria with a New 1,3,5-Triazine Derivative. Pharmaceuticals 2015,
8(4), 696-710.
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3.1 Abstract

Infections caused by multidrug-resistant bacteria have been on the rise. This important issue
presents a great challenge to the healthcare system and creates an urgent need for alternative
therapeutic agents. As a potential solution to this problem, antimicrobial peptides (AMPs) have
attracted increasing attention due to their broad spectrum of targeted microbes. However, most
AMPs are expensive to synthesize, have relatively high cytotoxicity to mammalian cells, and are
susceptible to proteolytic degradation. In order to overcome these limitations, novel synthetic
AMPs are desired. Using 1,3,5-triazine (TN) as a template, several combinatorial libraries with
varying cationic charge and lipophilicity were designed and screened by the Kallenbach lab.
From this screening, TN-5 was identified as a potent lead. In the present study, this compound
was tested for its antimicrobial activities on Escherichia coli and Pseudomonas aeruginosa. In
addition to regular planktonic cells, the effects on biofilms and persister cells (metabolically
inactive and antibiotic tolerant subpopulation) were also investigated. TN-5 was found to have a
minimum inhibitory concentration (MIC) of 12.8 µM for both species and kill regular planktonic
cells of both species dose dependently. TN-5 is also effective against persister cells of both E.
coli and P. aeruginosa. The killing of biofilm cells of the mucoid P. aeruginosa PDO300 was
enhanced by alginate lyase.
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3.2 Introduction
Since the discovery of penicillin in 1928 [1] and the achievement of economical production of
this antibiotic in the 1940s [2], the use of antibiotics has been a crucial step in controlling
infectious diseases with numerous lives saved [3]. However, the emergence and spread of
antibiotic resistant microorganisms have rendered many antibiotics ineffective [4]. Such rapid
development of multidrug resistant bacteria coupled with the insufficient investment in
antimicrobial research has led to a concerning decline in effective therapies against bacterial
infections, which presents a serious public health problem [5].
In addition to antibiotic resistance based on drug resistance genes [6], bacteria also exhibit high
level antibiotic tolerance by forming persister cells (dormant subpopulation of phenotypic
variants [7] and biofilms (surface attached structures with bacterial cells embedded in an
extracellular matrix secreted by attached cells [8]). Persister cells and biofilms are not based on
drug resistance genes; however, they allow bacteria to survive the treatment with potent
antibiotics and facilitate the development of drug resistant strains through mutation and
horizontal gene transfer [9].
According to the U.S. Centers for Diseases Control and Prevention, 80% of all infections in
developed countries are associated by biofilms [10]. The biofilm matrix serves as a protective
barrier, making bacterial cells more tolerant to antibiotics as well as host defense [11]. Biofilms
are also enriched in persister cells. Thus, even if an antibiotic can penetrate the biofilm matrix, it
might only kill normal cells within a biofilm population. After the course of antibiotic treatment,
persister cells revive and repopulate the biofilm, which in turn causes an infection to relapse
[10].
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An additional concern with biofilms of Pseudomonas aeruginosa is their ability to convert to
mucoid variants [12]. A mucoid strain is characterized by overproduction of the
exopolysaccharide alginate, with increased tolerance to some antibiotics [13] and phagocytosis
by human macrophages [14], as well as enhanced protection from dehydration [15]. In cystic
fibrosis patients, the leading cause of mortality is a respiratory failure due to chronic lung
infection with P. aeruginosa strains that undergo mucoid conversion [12]. Mucoid isolates
typically coincide with persistent chronic infection in cystic fibrosis patients.
The challenges of drug tolerant infections have created an urgent need for new antimicrobials
and treatment strategies. Recent research has shown the great potential of antimicrobial peptides
(AMPs) as a class of powerful agents against both Gram-positive and Gram-negative bacteria
[16,17]. A wide range of AMPs are naturally produced by the innate immune system of
multicellular organisms in response to infections [18]. These AMPs are a unique group of
molecules with a varying number of amino acids (generally from 12 to 50), including positively
charged residues (such as arginine, lysine, or histidine) and a large proportion of hydrophobic
residues. In humans, AMPs are found mainly in the tissues and organs that are exposed to
airborne pathogens [19].
The structure and charge of an AMP play a major role in the mechanism of its actions. AMPs are
generally cationic molecules with both hydrophobic and hydrophilic faces [20]. This
amphipathic characteristic helps these molecules to integrate into the lipid bilayer membranes
[21]. Membrane integrity disruption (via interaction with negatively charged cell membrane),
inhibition of macromolecule (protein, DNA and RNA) synthesis, or interaction with certain
intracellular targets are thought to be the primary mechanisms in AMP lethality [22]. Positively
charged side chains in AMPs enable an initial nonspecific electrostatic interaction with the
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negatively charged cell membrane. This process is followed by the insertion of AMP molecule
into cell membrane with the help of hydrophobic residues [23]. For example, in the AMPs LL-37
and β-defensin, the cationic face is positioned on the opposite side of the hydrophobic face,
which helps the penetration into the membrane [20].
AMPs afford promising candidates for novel therapeutic agents and complement traditional
antibiotic therapies because of some unique advantages, including broad-spectrum activity
(antibacterial, antiviral, and antifungal), less resistance by microbes, and related broad antiinflammatory activities [24]. A number of AMPs and derivatives have been developed as
therapies for infectious diseases such as oral mucositis [25], pulmonary infections associated
with cystic fibrosis [26], and some sexually transmitted diseases [27]. AMPs can be used alone,
in co-treatment with antibiotics, or as stimulators for immune system and toxin inhibiting agents
in septic shocks [24].
Despite the aforementioned advantages, wide applications of AMPs are still limited by several
factors. They are generally expensive to synthesize [28], vulnerable to proteolytic degradation
upon intravenous administration [29] and sensitive to environmental factors such as salt
concentration, pH, and the presence of plasma and serum proteins [30]. Another challenge is that
some AMPs are cytotoxic to host cells [31].
In order to overcome these challenges, a number of synthetic AMPs and AMP-mimetics have
been developed. Based on the concept that cationic charge, size, and lipophilicity are recognized
major factors determining the antibacterial activity of AMPs, recently, the Kallenbach lab
designed and screened several combinatorial libraries based on 1,3,5-triazine as a scaffold.
Several lead compounds with good antimicrobial activity and low hemolytic activity were
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identified from the screening of hundreds of triazine compounds [32]. With further structure
activity relationship analysis, the compound TN-5 was identified as a potent antimicrobial
compound (the screening results will be published elsewhere). In this study, TN-5 (Fig. 3-1) was
tested for its antimicrobial activity on E. coli and P. aeruginosa, including regular planktonic
cells, persister cells, and biofilms.

Figure 3-1. Chemical structure of TN-5.

3.3 Material and methods

3.3.1 Chemical synthesis of TN-5
TN-5, N2 - (4-Aminobutyl) - N4 - benzyl - N6 – naphthalenemethyl - 2,4,6 – triamino - 1,3,5triazine, white solid, was synthesized by our collaborator in Kallenbach lab at New York
University, using an orthogonal synthetic approach based on cyanuric chloride stepwise reaction
with naphthalenemethylamine, benzylamine and Boc-1,4-diaminobutane
previously [32].
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as documented

3.3.2 Bacterial strains and growth media
E. coli RP437 [33] was provided by Dr. John S. Parkinson at the University of Utah. P.
aeruginosa PAO1 [34] and P. aeruginosa PDO300 [12] were obtained from Dr. Matthew Parsek
at the University of Washington. All strains were routinely grown in Lysogeny broth (LB)
containing 10 g/L NaCl, 5 g/L yeast extract, and 10 g/L tryptone with pH 7.0. To ensure
consistent experimental conditions throughout this study, all overnight cultures of a particular
strain were started with single-use glycerol stocks originating from the same culture. Each
experimental condition was tested with three independent cultures (three biological replicates).

3.3.3 Determining Minimum Inhibitory Concentration (MIC) and Minimal Bactericidal
Concentration (MBC) of TN-5
TN-5 was tested at different concentrations against E. coli and P. aeruginosa strains to determine
MIC and MBC values following a previously described protocol [35] with slight modifications.
MIC is referred to the concentration of an antimicrobial agent, which inhibits the visible growth
of a given bacterium completely by checking with unaided eye. MBC is referred to the minimum
concentration of an antimicrobial agent required to completely kill all the tested bacterial cells of
a particular strain by checking colony formation on the plates after treatment. Briefly,
exponential cultures of bacterial samples were used to inoculate test samples with a cell density
of 5x105 colony forming unit (CFU)/mL. TN-5 was tested at concentrations from 0.2 µM to 96
µM, increasing logarithmically. Cultures grown without antimicrobial and sterile LB medium
were used as positive and negative controls, respectively. All samples were adjusted to a final
volume of 3 mL and incubated for 16-18 h at 37°C. After incubation, the concentrations with no
visible growth were assigned by visual check to determine MIC. MBC value of TN-5 was
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identified by spreading TN-5 (0.2 µM to 96 µM) treated cells (overnight in LB) on LB agar
plates and checking for growth after 24 h. Three independent cultures for each concentration
were tested for MIC and MBC tests.

3.3.4 Effects on planktonic cells
To examine the antimicrobial activity of TN-5, the planktonic growth of E. coli RP437, P.
aeruginosa PAO1 and PDO300 with TN-5 added at different concentrations was examined.
Overnight cultures of each strain were grown in 50 mL LB medium for 12-16 h at 37°C.
Subcultures were then prepared by inoculating LB medium with overnight cultures to an optical
density at 600 nm (OD600) of 0.01 and harvested when the OD600 reached 0.4-0.5. These
exponential cultures were washed with phosphate buffered saline (PBS) three times. Cell pellets
were washed with fresh PBS and resuspended in 20 mL PBS buffer. For the TN-5 treatment, 3
mL of each sample was taken and mixed with TN-5 at different concentrations. The samples
were incubated for 3, 6, 12 and 24 h at 37°C with shaking at 200 rpm, and washed three times
with PBS. Then a serial dilution of each sample was performed and the cells were spread on LB
agar plates for counting CFU. The amount of DMSO (solvent to dissolve TN-5 in stock
solutions) was adjusted to be the same for all samples to eliminate any solvent effect. Each
condition was tested with three independent cultures.

3.3.5 Persister isolation and treatment
To isolate persister cells, overnight cultures of P. aeruginosa PAO1 and P. aeruginosa PDO300
strains were treated with 200 µg/mL ciprofloxacin (Cip) while exponential cultures of E. coli
RP437 were treated with 100 µg/mL ampicillin (all for 3 h at 37˚C) to kill normal cells as
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described previously [36-38]. Then the persister cells were harvested by centrifugation, washed
with PBS three times to remove remaining antibiotic, and resuspended in 20 mL PBS. Aliquots
(1 mL) of each sample were supplemented with TN-5 at different concentrations. Three
replicates were tested for each condition and all samples were incubated for 3 h at 37°C with
shaking at 200 rpm. No change in persister cell number was found before and after incubation
for 3 and 6 h in PBS without TN-5 (regardless the presence of antibiotics; Fig. 3-2). After TN-5
treatment, the samples were washed with PBS three times and plated to count CFU as described
above. Each condition was tested with three independent cultures.

Figure 3-2. The isolated persister cells remained persistence after incubation in PBS. After
isolation, the persister cells were incubated with or without antibiotic for 3 and 6 h. The persister
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cells of E. coli RP437 (A), P. aeruginosa PAO1 (B), and P. aeruginosa PDO300 (C) were
studied. Ampicillin at 100 µg/mL and ciprofloxacin at 200µg/ml were used to treat E. coli and P.
aeruginosa persister cells, respectively.

3.3.6 Biofilm experiments
To study the effects of TN-5 on biofilm cells of E. coli and P. aeruginosa, biofilms were grown
on 2 cm x 1 cm 316L stainless steel coupons. Each coupon was polished with 220 Grit sandpaper
(3M, Sandblaster, St. Paul, MN) on both sides and sterilized with 70% ethanol for at least 15
min. The coupons were then dried in a 50°C oven for 15 min. Sterilization was confirmed by
incubating three coupons in LB medium for 24 h at 37°C and checking the turbidity of the
cultures. To culture biofilms, sterilized coupons were transferred into new sterile plates
containing 20 mL LB medium. To initiate biofilm formation, each sample was inoculated to
OD600 of 0.01 with an overnight culture. The coupons were incubated for 24 h at 37°C without
shaking to grow biofilms. After 24 h incubation the coupons were washed gently with PBS three
times to remove planktonic cells. Coupons were then placed in 12 well plates separately, each
including a different concentration of TN-5 in 2 mL PBS buffer. The coupons were incubated for
3 h at 37°C with no shaking followed by washing with PBS three times. Each coupon was then
transferred into a 15 mL sterile conical test tube containing 3 mL PBS. Samples were gently
sonicated for 4 min in a water sonication bath (Branson B200 Ultrasonic, Danbury, CT, USA)
and then vortexed for 15 s. Three replicates were tested for each condition. The cells in the
suspension were then spread on LB agar plates to count CFU as described above. Each condition
was tested with three independent cultures.
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Besides treating established biofilms, the capability of TN-5 to prevent biofilm formation was
also evaluated by adding TN-5 prior to the inoculation of biofilm cultures. After incubation for
24 h, the coupons were washed gently and the cells were removed from coupon surface by
sonication and vortex for CFU count as described above.

3.3.7 Co-treatment of alginate lyase and TN-5 on P. aeruginosa biofilm cells
To determine the contribution of a biofilm degrading agent on killing by TN-5, we repeated
biofilm killing experiments in the presence of 50 µg/mL alginate lyase during TN-5 treatments.
The same protocols were used for P. aeruginosa PAO1 and PDO300 biofilms. Each condition
was tested with three independent cultures.

3.3.8 Statistical analysis
The data from CFU experiments were analyzed with one-way ANOVA followed by Tukey test
using SAS version 9.4 (SAS Institute, Cary, NC, USA). Differences with p<0.01 were
considered as statistically significant.

3.4 Results
3.4.1 MIC and MBC values of TN-5
TN-5 was found to completely inhibit the growth of E. coli RP437, P. aeruginosa PAO1, and P.
aeruginosa PDO300 at the concentration of 12.8 µM (MIC, Table 1). The MBC value was found
to be higher than 96 µM for all three strains.
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Table 3-1. MIC and MBC values of TN-5 on bacterial strains used in this study (based on three
biological replicates).

MIC (µM)
MBC (µM)

E. coli RP437

P. aeruginosa PAO1

P. aeruginosa PDO300

12.8
> 96

12.8
> 96

12.8
> 96

3.4.2 Antimicrobial effects of TN-5 on planktonic cells
To further study the killing activity of TN-5, exponential cultures were used to test the effects of
TN-5 on the viability of planktonic cells. TN-5 was found effective in killing all bacterial strains
tested in this study (E. coli RP437, P. aeruginosa PAO1 and PDO300) dose dependently in 3 h
(Fig. 3-3). Longer incubation times (up to 24 h) did not cause additional killing (Fig. 3-4). For E.
coli RP437, TN-5 showed 20.3±2.5% (p=0.07), 55.6±8% (p<0.001), 84.6±8.5% (p<0.001), and
99.9±0.1% (3.4 log; p<0.001) killing of the total population (>99% as normal cells) at
concentrations of 5, 20, 50, and 100 µM, respectively (Fig. 3-3A). These results show that TN-5
is highly effective against normal planktonic cells of E. coli RP437.
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Figure 3-3. Effects of TN-5 on planktonic cells of E. coli RP437 (A), P. aeruginosa PAO1 (B),
and P. aeruginosa PDO300 (C). TN-5 was added in exponential phase cultures at different
concentrations and the viability after treatment was determined by counting CFU. All significant
differences (compared to the TN-5 free control) with p<0.01 are marked with an asterisk
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Figure 3-4. Extended treatment time did not increase the killing of planktonic cells of E. coli and
P. aeruginosa by TN-5. Each sample was treated with 100 µM TN-5 for 3, 6, 12, or 24 h. Three
independent replicates were tested for each condition. E. coli RP437 (A), P. aeruginosa PAO1
(B), and P. aeruginosa PDO300 (C) were studied.
Significant killing effects were also observed on planktonic cells of P. aeruginosa PAO1 and
PDO300 strains. For example, killing of 22.7±6.7% (p<0.001), 61.8±4.5% (p<0.001),
74.7±11.8% (p<0.001), and 97.8±10% (1.6 log; p<0.001) of P. aeruginosa PAO1 was observed
when TN-5 was added at 5, 20, 50, and 100 µM respectively (Fig. 3-3B). For P. aeruginosa
PDO300, significant killing was observed at 50 and 100 µM with 44.1±3.1% (p<0.001) and
94.1±6.8% (1.23 log; p<0.001) of the total population (>99% as normal cells) killed,
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respectively (Fig. 3-3C). These results show that TN-5 is also effective against normal
planktonic cells of P. aeruginosa.

3.4.3 Antimicrobial effects of TN-5 on persister cells
TN-5 was found to kill persister cells of E. coli RP437, P. aeruginosa PAO1 and P. aeruginosa
PDO300 (Fig. 3-5). The killing of E. coli RP437 persister cells was 33.8±0.8% (p<0.001),
43.8±2.8% (p<0.001), and 96.3±3.0% (1.35 log; p<0.001) when TN-5 was added at 50, 100, and
200 µM, respectively (Fig. 3-5A).
Similarly, TN-5 was also able to reduce the viability of P. aeruginosa PAO1 persister cells
where 79.6±2.9% (p<0.001) and 89.9±4.5% (p<0.001) of cells were killed by 100 μM and 200
μM of TN-5, respectively (Fig. 3-5B). In comparison, TN-5 was less effective on persister cells
of the mucoid strain P. aeruginosa PDO300, with only 33.2±5.6% (p<0.001) and 36.4±5.2%
(p<0.001) killed by 100 μM and 200 μM of TN-5, respectively (Fig. 3-5C). This is likely due to
the presence of alginate on the surface of the mucoid P. aeruginosa PDO300 cells [39], which
may reduce the penetration by TN-5.
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Figure 3-5. Effects of TN-5 on persister cells of E. coli RP437 (A), P. aeruginosa PAO1 (B),
and PDO300 (C). The persister cells were isolated by treating exponential cultures of E. coli
RP437 with 100 µg/mL ampicillin and overnight P. aeruginosa cultures with 200 µg/mL
ciprofloxacin (both for 3 h). All significant differences (compared to the TN-5 free control) with
p<0.01 are marked with an asterisk.
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3.4.4 Antimicrobial effects of TN-5 on biofilm cells
TN-5 exhibited effective and dose dependent killing of E. coli RP437 biofilms. Killing of
78.5±30.2% (p<0.001) and 98.9±9.6% (1.24 log) (p<0.001) of E. coli RP437 biofilm cells was
achieved when TN-5 was added at 100 and 200 µM, respectively (insignificant at 50 µM) (Fig.
3-6). In addition to the effects on established biofilms of E. coli RP437, TN5 effectively
prevented biofilm formation of all the strains used in this study. Complete biofilm inhibition of
E. coli RP437 and P. aeruginosa (both PAO1 and PDO300) was achieved with 10 and 20 µM
TN-5, respectively (Fig. 3-7). However, 100 µM TN-5 alone did not show significant killing of
cells in established biofilms of P. aeruginosa PAO1 or PDO300 (p>0.1) (Fig. 3-8A and 3-8C).

Concentration of TN‐5 (µM)

Figure 3-6. Effects of TN-5 on E. coli RP437 biofilms. The biofilms were cultured for 24 h in
LB on stainless steel coupons prior to treatment with TN-5. All significant differences (compared
to the TN-5 free control) with p<0.01 are marked with an asterisk. Note: Data are plotted in
linear scale.
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Figure 3-7. Effects of TN-5 on biofilm formation of E. coli RP437 (A), P. aeruginosa PAO1
(B), and P. aeruginosa PDO300 (C). Initial biofilm cultures were supplemented with TN-5 at
different concentrations and incubated for 24 h at 37˚C. Then coupons were sonicated and
vortexed to count CFU in biofilms. Three independent replicates were tested for each condition.
All significant differences (compared with the TN-5 free control) with p<0.01 are marked with
an asterisk.
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Figure 3-8. Effects of TN-5 alone and co-treatment with alginate lyase on P. aeruginosa
PDO300 (A&B) and PAO1 (C&D) biofilms. The biofilms were grown for 24 h and treated with
TN-5 alone or in combination with alginate lyase for 3.5 h. All significant differences (compared
with the TN-5 free control) with p<0.01 are marked with an asterisk. The co-treatment with TN5 (at 50 or 100 µM) and 50 µg/mL alginate lyase caused significant killing than the control (with
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no TN-5 and alginate lyase) for both P. aeruginosa PDO300 and PAO1, but only significantly
increased the killing by TN-5 alone for P. aeruginosa PDO300. Note: Data are plotted in linear
scale.
We speculated that the lack of antimicrobial effects against P. aeruginosa biofilms is because of
the presence of biofilm matrix. Alginate is a major component of biofilm matrix of the mucoid P.
aeruginosa strains [13,39]. Thus we tested the concurrent treatment of P. aeruginosa biofilms
with alginate lyase and TN-5. As shown in Fig. 3-8B and 3-8D, alginate lyase itself showed no
effect on the viability of biofilm cells (p=1). However, the combination of TN-5 with alginate
lyase increased the killing of PDO300 biofilms; e.g., addition of 50 µM alginate lyase increased
the activity of 50 µM TN-5 on P. aeruginosa PDO300 biofilms from no significant killing
(p=0.58) to 36.5±4.6% (p<0.005) and that of 100 µM TN-5 from insignificant killing (p=0.12) to
57±9.6% (p<0.005), respectively (Fig. 3-8A vs. Fig. 3-8B). The addition of alginate lyase did
not show the same effects on P. aeruginosa PAO1 biofilm cells; e.g., 50 µM alginate lyase did
not increase the effects of 50 and 100 µM TN-5 (p>0.1) (by comparing the % of killing based on
corresponding data between Fig. 3-8C & Fig. 3-8D). This is likely because alginate is not a
major component of its biofilm matrix.

3.5 Discussion

AMPs have been proposed as a promising source of new antimicrobial agents [40-43]. Different
strategies have been tested to achieve effective killing of microbes while maintaining low
hemolytic activity. In some of these studies, Trp (W) and Arg (R) containing 1,3,5-triazine
structures [32] and dendrimeric peptides [44] have been used as AMP templates and lead
compounds with antimicrobial activities and low toxicity to red blood cells have been identified.
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In this study, one of the triazine-1,3,5 derivatives, TN-5, was tested on Gram-negative bacteria E.
coli and P. aeruginosa. TN-5 was found to be effective against both species. The killing of
persister and biofilm cells is of particular interest because these cells are difficult to eliminate
and conventional antibiotics are generally ineffective. Our results show that TN-5 alone is
effective against persister and biofilms of E. coli RP437 with up to 2-log killing achieved at 200
µM. It is also interesting that TN-5 caused more killing of biofilm cells than planktonic persister
cells of E. coli. For example, 100 µM TN-5 killed 43.8±2.8% and 78.5±30.2% of persister and
biofilm cells of E. coli RP437, respectively. This finding suggests that TN-5 can penetrate the
biofilm matrix of E. coli.
Comparable effects were not observed for P. aeruginosa biofilms, however, possibly due to the
difference in biofilm matrices. With a thick layer of alginate, biofilms of mucoid bacteria have
high-level tolerance to some antimicrobials [13]. Thus, breaking down alginate in the biofilm
matrix could be essential for certain antimicrobials to kill biofilm cells, especially the agents that
can be absorbed or neutralized by the matrix components. Consistently, we found that the killing
of P. aeruginosa PDO300 biofilm cells was enhanced by alginate lyase. It is worth noting that
TN-5 is effective against P. aeruginosa PDO300 persister cells, but not its biofilm cells. Thus, it
will be interesting to study if and how TN5 interacts with alginate directly and if there is any
difference in the amount and structure of alginate between biofilm matrix and the surface of
mucoid cells. In comparison, the killing of P. aeruginosa PAO1 biofilms was not enhanced by
alginate lyase. This is consistent with the report [45] that alginate is not the primary component
of P. aeruginosa PAO1 biofilm matrix. It will be interesting to test other matrix degrading
enzymes, such as DNase.
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In a previous study performed in our lab, Trp- and Arg- containing synthetic antimicrobial
peptides were shown to inhibit 95.0 ± 1.1% of biofilm formation at 200 µM [46]. Intriguingly,
TN-5 inhibited biofilm formation of both E. coli and P. aeruginosa completely at 20 µM (Fig. 37). Therefore, TN-5 may also be an important antimicrobial agent for biofilm control.
The mechanism of bacterial killing by TN-5 or in fact any AMP deserves more study. The
positive charge of the arginine (R) side chain can help an AMP to interact with negatively
charged lipopolysaccharides in Gram-negative bacterial walls [47]. Tryptophan (W) residues
favor location below the head groups of bilayers, and are assumed to provide lipophilic
interaction sites which cause membrane disruption [48]. Thus, RW mimicking TN-5 might target
the negatively charged bacterial cell membrane. Another observation is that TN-5 mode of action
occurs within the first 3 h (Fig. 3-2).
E. coli is generally more susceptible to antibiotics than P. aeruginosa. Among 47 antimicrobial
agents tested in an early study [49], only tobramycin showed the same MIC value (0.5 µg/mL)
for E. coli (NCTC 10418 and ATCC 25922) and P. aeruginosa (NCTC 10662 and ATCC 27853)
reference strains. The other antimicrobial agents tested all showed higher (up to 500 fold) MIC
values for P. aeruginosa compared to E. coli [49]. Interestingly, TN-5 showed the same MIC
value (12.8 µM) for both species in our study, which also indicates possible membrane targeting
activities.
Overall, this study shows that the triazine derivative TN-5 is a promising lead compound for
developing new synthetic AMPs. It is encouraging that TN-5 is effective against both E. coli and
P. aeruginosa at different growth stages. Persister cells of Pseudomonas strains, especially those
of the mucoid strains, are highly resistant to antibiotic treatments. Because most AMPs kill
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microbes through mechanisms that differ from those of conventional antibiotics, e.g. by targeting
cell membranes, the killing effect of TN-5 on persister cells might be increased by synergy with
some antibiotics if TN-5 can be effectively delivered to target cells. We assume that triazines are
not susceptible to proteolytic degradation since there is no specific motif to trigger cleavage.
Future experiments with mammalian cells and animal models are needed to evaluate the
potential to use TN-5 and antibiotics together as a novel therapy for chronic infections involving
biofilms and persister cells.
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CHAPTER 4

CONTROLLING PERSISTER CELLS BY TARGETING MEMBRANE POTENTIAL
DEPENDENT ANTIBIOTIC EFFLUX
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4.1 Introduction
Persister cells were first defined in 1944 when Bigger showed surviving Staphylococcus after
penicillin treatment. Re-inoculation of surviving cells gave rise to colonies, the majority of
which can again be lysed by penicillin [1]. Forming metabolically inactive cells is one of the
major strategies of bacterial survival in harsh conditions such as antibiotic treatments and host’s
immune reactions. These dormant persister cells are highly tolerant to antibiotics and thus serve
as a reservoir for the population to reestablish after the treatment leading to recalcitrance of
chronic infections [2].
To date, the mechanism of persister formation and physiological characteristics of persister cells
are still not fully understood. Shah et al. [3] labeled E. coli ASV cells with a unstable GFP to
follow cell growth activities with fluorescence under the control of ribosomal rrnBP1 promoter.
Fluorescence-activated cell sorting (FACS) based on GFP gave two distinct populations; the
bright normal cells and dim persister cells. Visualization with microscopy and further antibiotic
treatment of these two populations revealed that persister cells are shorter than normal cells.
Persister also exhibits a gene expression profile with increased level of SOS stress response,
phage-shock and heat and cold-shock genes [4].
Previous efforts to determine the genes specifically responsible for persister formation by
screening knock-out mutant libraries have been largely unsuccessful [5,6]. Increasing evidence
indicated that there are redundant pathways leading this dormancy stage. Some best
characterized systems associated with persistence include toxin/antitoxin (TA) modules and the
SOS response system. For example, persister cells have increased level of TisB protein, which
decreases proton motive force and the ATP level and thus causes the cells to enter dormancy [2].
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Essentially all bacterial populations include a small portion of persister cells [7]. These cells
have low cellular energy due to their dormancy. Normal bacterial cell membrane has relatively
high transmembrane potential, between –120 to –200 mV, which is important to ATP production
and provides energy for many cellular processes [8]. Thus we hypothesize that persister cells
have lower membrane potentials than normal cells and this temporary metabolic downshift might
inactivate efflux based antibiotic resistance mechanism leading to intracellular accumulation of
antimicrobials and kill persister cells during wakeup.
Bacterial cell membrane is a semipermeable phospholipid bilayer with embedded proteins. This
membrane plays an important role in the growth and stress response of bacteria. It is also the part
of cell that antibiotics must penetrate to take action. The membrane permeability is affected by
its composition [9]. Transporters, ion channels, ATP synthases, receptors, antigens and some
signaling proteins are found in the membrane and represent about one third of the total proteins
in a cell. These proteins are responsible for many important biological functions such as cell–cell
contact, surface recognition, signaling, enzymatic activities, and transporting substances across
the membrane [10]. An important function of cell membrane is to generate proton motive force,
which requires the activities of ATP synthases, motility, DNA repair, and synthesis of
macromolecules such as polysaccharides, proteins, nucleic acids, and numerous other processes
in all living cells. Therefore, disturbance of membrane potential may have profound effects on
the physiology and viability of bacterial cells.
Energy-dependent drug efflux systems embedded in cell membranes play an important role in
bacterial drug resistance [11,12], which requires proton motive force generated with appropriate
membrane potential [13]. Most efflux pumps are proton pumps with a broad spectrum of target
substrates [14]. For example, E. coli cells are resistant to erythromycin molecules via such efflux
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pumps [15] and this activity depends on the energy produced by ATP synthase [16]. Some efflux
pumps and their substrate antibiotics are summarized in Table 4-1.

Table 4-1. Bacterial efflux pumps and substrate antibiotics
Efflux
family

Efflux
pump

Resistance against

Ref

RND

AcrAB

Eyrthromycin, tetracycline, chloramphenicol,
clarithromycin, ampicillin, nalidixic acid, and
rifampin

[17, 18]

ABC

YbjYZ

Clarithromycin, azithromycin, erythromycin

[15, 19]

MFS

MdfA

Rifampin, tetracycline, chloramphenicol

MATE

NorM,
YdhE

Norflaxacin, fluoroquinolones, rhodamine 6G,
acriflavine, berberine, novobiocin, enoxacin, and
tetraphenylphosphonium chloride

SMR

EmrE

Tetracycline and tetraphenylphosphonium

[20]
[21-23]

[24]

It has been reported that efflux pump mutants of Mycobacterium accumulate more ethidium
bromide (EtBr) inside the cells and consequently higher susceptibility to antimicrobials; such as
rifampicin, ethambutol, ciprofloxacin, streptomycin, amikacin, clarithromycin and erythromycin
[25]. All these antimicrobial agents act on energy-dependent metabolic pathways such as RNA
synthesis (rifampicin), cell wall synthesis (ethambutol [26]), protein synthesis (streptomycin,
amikacin, clarithromycin, and erythromycin [27-30]), and function of DNA gyrase [31].
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Efflux pumps have a wide variety of substrate antibiotics. For example, erythromycin,
tetracycline and chloramphenicol, which target protein synthesis by binding and inhibiting
ribosome complex, are all substrates of RND efflux family. These pumps are widespread
especially in Gram-negative bacteria and are active against many different antibiotics [32].
To test if persister cells have lower membrane potentials than normal cells, we characterized the
membrane potential and efflux activities of normal and persister cells of E. coli and compared
the killing effects of erythromycin, chloramphenicol and tetracycline on normal and persister
cells of E. coli. These antimicrobial agents were chosen among ribosome targeting antibiotics.
Under normal conditions E. coli efflux pumps use these antibiotics as substrate [18, 33-36].
However this efflux pump activity requires membrane potential and proton motive force.
Therefore lower membrane potential may result in accumulation of antibiotics in treated cells.
Erythromycin, which is a macrolide antibiotic, generally shows bacteriostatic effect by inhibiting
protein synthesis. Since it targets the ribosome complex, the production of all the peptides
including the ones essential to bacteria survival is inhibited. Erythromycin is used to treat several
serious bacterial infections, such as pneumonia, bronchitis, diphtheria, pertussis, rheumatic fever,
and epithelial infections. In 1986 no clinical isolate was found resistant to erythromycin [37];
however, a study in 2009 [33] showed that the majority of bacterial strains among 190 isolates
collected from 5 different countries have MIC values higher than 128 µg/mL, indicating a rapid
development of resistance. Erythromycin susceptibility can be restored with an AcrAB-TolC
efflux pump inhibitor in E. coli [18]. Therefore, we hypothesize that lower membrane potential is
expected to inhibit the activity of efflux pumps and increase the susceptibility of E. coli cells to
erythromycin.
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4.2 Materials and Methods

4.2.1 Efflux activity

The activity of efflux pumps was monitored with EtBr, by measuring its accumulation inside the
cells. EtBr gives strong fluorescence when interacting with nucleotides [38] and can be pumped
out by efflux systems of E. coli in the presence of proton motive force across cell membrane.
Thus, the accumulation of EtBr inside the cells is a cumulative result of membrane permeability
and efflux activity [39].
E. coli Top10 pBAD hipA, a strain with inducible persister formation (engineered by Jing Wang
in Ren lab) was used to test efflux activities. This strain can form large number of persister cells
upon induction of hipA gene expression by 0.2% arabinose. E. coli Top10 pBAD hipA culture
was grown in Lysogeny broth (LB) containing 10 g/L NaCl, 5 g/L yeast extract, and 10 g/L
tryptone with pH 7.0.
To induce persister formation, O/N culture of E. coli Top10 pBAD hipA was sub-cultured with a
starting cell density of 0.01 at OD600 and incubated till the OD600 reached 0.15-0.2. Then the
culture was supplemented with 0.2% arabinose and incubated for another 3 h at 37˚C with
shaking at 200rpm to induce the persister formation. Additionally, 50 µg/mL tetracycline was
added and incubated for 0.5 h following arabinose induction for further persister formation. After
induction with arabinose and tetracycline, the culture was harvested by centrifuging at 10,000g
for 8 minutes and resuspended in PBS by gently vortexing for 15 seconds. These cells were
washed again with PBS and used for EtBr staining and persister count.
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A portion of each induced and uninduced sample was taken and used to determine the
persistence level by treating with 100 µg/mL ampicillin and counting CFU. The rest of each
sample was treated with 25µg/ml EtBr to evaluate membrane permeability by measuring
fluorescent signal from EtBr-nucleic acid complex of the cells. Following EtBr treatment, the
cells were washed with PBS to get rid of excess EtBr signal in extracellular media and 200 µL
cell suspension from each treatment was plated in a clear bottomed black walled 96 well plate for
measuring fluorescence using a microplate reader (model FLx800, Bio-Tek Instruments,
Winooski, VT, USA) with excitation at 360 nm and emission at 590 nm in PBS. Each
experimental condition was tested with three independent cultures (three biological replicates).

4.2.2 Flow-cytometer compensation and analysis of EtBr treated samples
Flow cytometry was used to corroborate the results following persister induction and EtBr
staining. To compare with the results of the wild-type E. coli K12, we also tested a ΔacrB mutant
strain obtained from the Keio collection [40]. This mutant lacks efflux pump activity regardless
the membrane potential. The exponential cultures of E. coli ΔacrB were stained with 25µg/ml
EtBr for 10 minutes. Then excess EtBr dye was washed away with PBS. The changes in
fluorescence intensity were determined using flow cytometry (Fig. 4-1).
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Laser

Figure 4-1. The principle of flow cytometry. The cells are dispersed in a stream of fluid so that
they can individually travel through fine tubing and detected. The signal from each event is
recorded by a computer and analyzed.
To test EtBr staining of persister cells with flow cytometry, an exponential culture of E. coli
Top10 pBAD hipA was induced with 0.2% arabinose as described previously and compared with
an uninduced control by staining with EtBr and analyzing with flow cytometry. In addition to the
efflux mutant and high persistence strain, exponential culture of E. coli ASV strain was also used
with flow cytometry to test if there is a higher EtBr accumulation in persister cells (dim
population).
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4.2.3 Comparing membrane potential of persister and normal cells with potentiometric
dye and flow cytometry
To corroborate the EtBr results and further understand if persister formation affects membrane
potential, we used a potentiometric dye, JC-1, to compare the membrane potential of normal
planktonic cells and persister cells. JC-1 stains mitochondria and bacterial cells based on
membrane potential [41]. This dye can give two different colors; red fluorescence when the dye
molecule aggregate and green fluorescence from free dye molecules. With a high membrane
potential, more JC-1 molecules can aggregate on the membrane and emit red fluorescence. In
comparison, when the membrane potential lowered; less JC-1 accumulates in the membrane.
This leads fluorescence dye in cytoplasm to give a green color. Thus a shift in red/green
fluorescence can indicate the change in membrane potential.
To perform this experiment, a high persistence strain, E. coli Top10 pBAD hipA, was grown
exponentially at 37°C by shaking with 200 rpm till OD600 reached 0.2-0.3. Then the cells were
washed with centrifugation and resuspended in PBS. Ten µL JC-1 dye was added per 100 – 300
µL cell sample. After gentle mix by slightly tapping the tubes, cell and potentiometric dye
mixture was incubated at 37°C for 15 minutes in dark. After incubation, the cells were
centrifuged and excess JC-1 dye was washed away. Immediately after washing, samples were
analyzed with flow cytometry by monitoring green and red fluorescence.

4.2.4 Activity of efflux substrate antibiotics on persister cells
Persister cells of E. coli HM22 and Top10 pBAD hipA strains were isolated as described
previously. Isolated persister cells were treated with erythromycin, tetracycline and
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chloramphenicol for 3.5 h at 37°C with 200 rpm shaking. After the treatment, surviving persister
cells were washed twice with PBS buffer to remove any remaining antibiotic. The collected cells
were resuspended in PBS plated to determine the viability by counting CFU as described
previously.

4.2.5 Erythromycin accumulation of persister cells
To verify if persister cells did accumulate more erythromycin than normal cells, we conducted an
experiment to treat the cells with erythromycin first and compared the antimicrobial activities of
the lysates from these cells. We also directly measured the intracellular concentration of
erythromycin using mass spectrophotometry (MS).
Briefly persister cells were isolated from exponential cultures of E. coli HM22 by treating with
100µg/mL Amp for 3.5 hours to kill normal cells. The CFU of normal and persister cell culture
samples were normalized based on OD600 readings. Both samples were treated with 100 µg/mL
erythromycin in PBS for 10 minutes. Then cells were collected by centrifugation and supernatant
samples were stored at -20˚C till MS analysis and killing experiment. The cell pellets were
sonicated (5 cycles at 100% amplitude with 30 s treatment for each cycle in ice-water) and
pipetted up and down to disrupt the cell membrane. Then, cell lysates were filtered through 0.2
µm filters and sent for MS analysis to Dr. Myriam Cotton at Hamilton College, Clinton, NY. A
13

C labeled erythromycin was used as an internal standard to verify the molecular weight of

erythromycin used in this study. The samples were also tested on fresh planktonic cultures of E.
coli HM22 for their killing activity and compared to that of 50 µg/ml erythromycin.
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4.3 Results

4.3.1 Efflux activity of normal and persister cells

The induction of persister formation with arabinose was successful and the persister population
was 0.16% in uninduced sample, and 17% with induction with arabinose and Tet. The isolated
persister cells were treated with EtBr solution to see if persister cells could accumulate more
EtBr intracellularly due to lower activity of efflux pumps. As expected, it was found that the
induced sample had 29.9±1.6% more EtBr signal than uninduced sample after 10 minutes of
incubation (Fig. 4-2).

Figure 4-2. Ratios of EtBr signal of induced cells / uninduced cells. EtBr signals were measured
using a fluorescence microplate reader (model FLx800, Bio-Tek Instruments, Winooski, VT,
USA) with excitation at 360 nm. The ratios; 1.12±0.8%, 24.3±3.2%, 29.9±1.6%, and 18.9±1.5%
at 0, 5, 10, and 30 minutes after adding EtBr are shown.
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4.3.2 Flow cytometry analysis of efflux activity with EtBr staining
The results show that adding EtBr caused E. coli ΔacrB cells, which have no efflux activity, to
shift from low red fluorescence (less than 103) to high red fluorescence area (higher than 103)
(Fig. 4-3). This finding proves that EtBr accumulates inside the cells if the efflux activity is not
present, and demonstrates that flow cytometry analysis with EtBr staining is effective in
membrane potential studies.

Figure 4-3. Flow cytometry data showing fluorescent signals of unstained and EtBr stained E.
coli ΔacrB cells. The cells were analyzed for their green (FL1) and red (FL2) fluorescence. A1)
and A2) are unstained samples while, B1) and B2) are EtBr stained samples.
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4.3.3 Persister induction
E. coli Top10 pBAD hipA (Fig 4-4 A1 and 4-4 A2) cells that were not induced for persister
formation did not show significant fluorescent signal after incubation with EtBr for 10 min (Fig.
4-4 B1 and 4-4 B2). In contrast, 13% of the cells in arabinose induced sample (circled with red
dotted line) showed more than 10 fold higher red fluorescent signal than the rest of the
population and uninduced cells. Consistently, 18% of cells in this sample were confined to be
persister cells based on CFU results. This finding shows that the persister population of E. coli
Top10 pBAD hipA strain has lower efflux activity compared to normal cells, which is consistent
with the results of E. coli ΔacrB efflux mutant. Since the efflux pump activity depends on
membrane potential, these results suggest that persister cells have lower membrane potential than
normal cells.
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Figure 4-4. Persister formation led to increase in intracellular concentration of EtBr. A1 and A2;
no induction and no staining, B1 and B2; without induction of persister formation, but with EtBr
staining, C1 and C2; with induction of persister formation and EtBr staining. E. coli Top10
pBAD hipA was used in all the tests.

In addition to high level persistence strain, E. coli ASV which only has around 0.1% persister
ratio was also tested with flow cytometry for their dim color compared to green active
exponential cells with no staining. This small number of persister cells showed up as a distinct
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population plot in cytometry analysis (Fig. 4-5). This strain is only green when the cells are
active, and persister cells did not show any green color.

Figure 4-5. Flow cytometry analysis of E. coli ASV strain. Red circle shows the dim persister
population.

4.3.4 Comparing membrane potential of persister and normal cells with potentiometric
dye and flow cytometry
We further tested membrane potential using, E. coli Top10 pBAD hipA with and without the
induction of persister formation with 0.2% arabinose. Fig. 4-6 shows that the induced persister
formation led to decrease in red fluorescence, while the level of green fluorescence (stains all
cells) did not change. This reduced level of red fluorescent suggest that less JC-1 dye molecules
accumulated on the membrane due to lower membrane potential.
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Figure 4-6. Potentiometric staining and flow cytometry results of uninduced (A1-A3) and
induced (B1-B3) E. coli Top10 pBAD hipA cells. A2) and B2) show the signal of green
fluorescence while A3) and B3) show the signal of red fluorescence.

4.3.5 Activity of efflux substrate antibiotics on persister cells

Among tested antibiotics 50µg/ml erythromycin killed 78.2% of E. coli HM22 persister cells
after 3 h (Fig. 4-7B) while the same concentration has less than 30% killing on normal cells (Fig.
4-7A). This higher killing effect of erythromycin on persister cells could only be repeated when
PBS is used as washing and treatment buffer. This indicates presence of some ions helped
erythromycin effect to kill persister cells.
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Figure 4-7. Effects of erythromycin on the viability of E. coli normal (A) and persister (B) cells.
The number of cells before treatment was normalized as 100%.

4.3.6 Intracellular accumulation of erythromycin
As shown in Fig. 4-8, lysate from erythromycin treated persister cells exhibited higher killing
activity on E. coli HM22 cells than that from erythromycin treated normal cells. As negative
controls, cell lysates without pretreatment with erythromycin did not cause any significant
change in cell viability (less than 4%). The killing by the lysate of persister cells treated with
erythromycin pellet was 18.1 ± 3.6%, similar to while it was 19.4 ± 4.7% by adding 50 µg/mL
erythromycin directly. This suggests that persister cells accumulated a high concentration of
erythromycin.
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% killing ratio

Figure 4-8. Antimicrobial effects of cell lysates from erythromycin treated normal & persister
cells of E. coli HM22. NC; normal cells, PC; persister cells. In total 8 types of samples were
tested; NExEr (normal cells extracellular erythromycin, Fig. 4-9), NInEr (normal cells
intracellular erythromycin, Fig. 4-10), PExEr (persister cells extracellular eryhtromycin, Fig. 411), PInEr (persister cells intracellular eryhtromycin, Fig. 4-12), NEx13 (normal cells
extracellular

13

C labeled eryhtromycin, Fig 4-13), NIn13 (normal cells intracellular

13

C labeled

eryhtromycin, Fig 4-14), PEx13 (persister cells extracellular 13C labeled eryhtromycin, Fig 4-15),
PIn3 (persister cells intracellular 13C labeled erythromycin, Fig 4-16).
Consistent with the CFU results, MS analysis revealed that persister cell pellet had relatively
higher erythromycin accumulation compared to normal cells. As shown in Table 4-2, the
extracellular erythromycin levels were significantly higher (at least 14 fold) than the intracellular
erythromycin level in normal cells. This result confirmed that normal cells can actively pump out
erythromycin. In contrast, this ratio becomes much lower (1.6) for persister cells (8.7 fold
decrease). This finding suggests that persister cells can not actively pump the erythromycin out.
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Figure 4-9. Mass Spectrophotometry analysis of erythromycin level in the extracellular
supernatant of normal cell samples

Figure 4-10. Mass Spectrophotometry analysis of intracellular erythromycin level in normal cell
samples

Figure 4-11. Mass Spectrophotometry analysis of erythromycin level in the extracellular
supernatant of persister cell samples
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Figure 4-12. Mass Spectrophotometry analysis of intracellular erythromycin level in persister
cell samples

Figure 4-13. Mass Spectrophotometry analysis of 13C labeled erythromycin level in the
extracellular supernatant of normal cell samples.

Figure 4-14. Mass Spectrophotometry analysis of intracellular 13C labeled erythromycin level in
normal cell samples
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Figure 4-15. Mass Spectrophotometry analysis of 13C labeled erythromycin level in the
extracellular supernatant of persister cell samples

Figure 4-16. Mass Spectrophotometry analysis of intracellular 13C labeled erythromycin level in
persister cell samples

Table 4-2. Ratios of intracellular vs extracellular concentration of erythromycin. The
concentrations were determined using MS analysis.
Relative ratio between

Value (fold)

NExEr/NInEr

30.2

NEx13/NIn13

14

PExEr/PInE

1.4

PEx13/PIn13

1.6
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4.4 Discussion

Normal E. coli cells pump EtBr out by AcrAB-TolC efflux pumps [42]. Erythromycin is also a
substrate of this efflux pump [18]. Consistently E. coli ΔacrB, which has a nonfunctional
AcrAB-TolC pump, showed high level of EtBr accumulation in flow cytometry experiments
(Fig. 4-3B1, 4-3B2).
Having more EtBr accumulation in persister cells (Fig 4-2) suggests that persister formation does
cause lower efflux activities since inactive efflux pumps cannot extrude EtBr.

The slight

decrease in decrease in signal level after 10 minutes can be explained by cell damage or death
due to the toxic effects of prolonged EtBr treatment on E. coli cells [43].
Since the frequency of persister formation is generally low [2], we tested with a high persistence
strain, E. coli Top10 pBAD hipA, using flow cytometry to determine efflux activities of persister
cells. As seen in Fig. 4-4, EtBr signals of the population shifted to red fluorescence and a
population of persister cells was distinguished with even higher red signal. These data also
support the low efflux activities in persister cells, as a result of dormant nature of persister cells.
These efflux activity results were corroborated with a potentiometric dye, JC-1, which can
directly label the potential of a cell membrane [44,45]. When the arabinose induced E. coli
Top10 pBAD hipA was stained with JC-1 dye and analyzed using flow cytometry, a small
subpopulation with low red color was detected. The amount of cells in this population correlates
well with the persistence level, further support that persister cells have lower membrane
potentials than normal cells.
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In parallel to membrane potential experiments, we also studied the effect of some ribosome
targeting antibiotics, which are also the substrates of the AcrAB-TolC pump efflux system [18],
[33]. Erythromycin, tetracycline and chloramphenicol are all substrates of E. coli AcrAB-TolC
pumps [18, 33-36]. Because persister cells have reduced membrane potential & efflux activity,
we expect these antibiotics can accumulate more intracellularly in persister cells. Interestingly,
erythromycin showed higher killing effect on persister cells than normal cells. Since efflux pump
activity is essential for the resistance to erythromycin [46], we speculated that this higher killing
activity against persister cells may be caused by inactive efflux pumps due to low membrane
potential of these cells which led to accumulation of more erythromycin molecules in persister
cells.
It has been reported that tetracycline uptake occurs with both energy dependent and independent
mechanisms [47]. E. coli cells in exponential cultures are susceptible to tetracyline while the
persister cells are tolerant. This energy dependent cellular uptake of tetracycline might explain
why normal cells are more susceptible compared to dormant persister cells, which is different
from the results of erythromycin.
As illustrated in Fig. 4-17, erythromycin molecules diffuse into the cells [48], regardless of the
metabolic stage. This antibiotic kills bacterial cells by binding to ribosomal complex and
inhibiting protein synthesis [49]. In active cells, efflux proteins can pump erythromycin out
before they reach and bind to the target. Persister cells have lower membrane potential, and thus
inactivate efflux systems. Therefore more erythromycin will accumulate in the cells and target
the ribosome complex during wakeup (on agar plates), leading to bacterial killing.
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Figure 4-17. Schematic of possible effects of erythromycin on normal (A) and persister (B) cells

Normally E. coli is resistance to erythromycin and susceptible to tetracycline. However, we have
observed higher killing with erythromycin on E. coli persister cells while the cells were not
affected with tetracycline treatment. Erythromycin is a bacteriostatic antibiotic [50] which means
it requires bacterial activity to inhibit and eventually kill the bacteria. The activity of
erythromycin also requires the presence of K+ ions for binding to ribosome [49,51,52].
Consistently, when 0.85% NaCl solution rather than PBS was used to wash the cells, persister
killing by erythromycin was not observed. Erythromycin forms a very stable complex with its
target ribosome. The dissociation constant of eryhtromycin and ribosomes is between 1.1x10-7
and 3.4x10-7 M [53]. In comparison, the dissociation constant between tetracycline and its target
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is 1x10-6 [54], a magnitude higher than erythromycin. Collectively, the differences in binding
strength may explain why the other two antibiotics did not show similar effects as eryhtromycin
since their diffusion is faster than wake up upon removal of antibiotics.
In the case of chloramphenicol, the binding is even weaker than tetracycline; e.g; the dissociation
constant is 2x10-6 [55]. Besides, chloramphenicol uptake by Gram negative bacteria is suggested
by means of an energy-dependent processes [56]. These two reasons might explain why
chloramphenicol could not show killing effect on persister cells. These results revealed that there
are weaknesses of persister cells, which can be targeted by antimicrobials to achieve killing of
this dormant population.
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CHAPTER 5

NEW AMP DERIVATIVES OF CALCITERMIN AND THEIR EFFECTS ON
PSEUDOMONAS AERUGINOSA and ESHERICHIA COLI
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5.1 Introduction
The growing interest in AMPs, also defined as natural microbicidals [1],

as alternative

antimicrobial agents to current antibiotics is also favored by their low propensity to induce drug
resistance [2]. Native AMPs can serve as a source of antimicrobial agents for treatment of
different infectious diseases. However, clinical use of native AMPs have issues such as potential
toxicity to human cells and proteolytic degradation. Thus many studies have been conducting to
search for better AMPs by re-designing native antimicrobial peptides recently [3]. For example,
dermicidin secreted from epihelia can be further improved by removing 23 amino acid from Nterminal end to have 2-fold increase in killing activity against E. coli [4] and this new derivative
of dermicidin can be more effective in skin infections. This will also adress concerns related to
the stability of AMPs. Efforts have also been made to generate and screen AMP libraries based
on native AMPs to study a large number of candidates simultaneously. This allows identification
of important features in AMP structures and physiochemical properties required for specific
activities of AMPs [1].
AMPs from different sources identified to date have provided important information for
designing new sythetic AMPs with improved antimicrobial effects, target spectrums, and
stabilities under different physiological conditions along with reduced cost due to short amino
acid sequences [3].
We hypothesized that some human originated natural AMPs can be further improved to kill
bacterial persister cells by and optimizing their physiochemical characteristics. Specifically, we
studied the effects of the net charge of an AMP on planktonic & persister cells of E. coli and P.
aeruginosa.
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Among these AMPs we selected calcitermin, which has 15 amino acid in length with a net
charge of “+1” and an α-helical structure [5], to study the effects of AMP net-charge on the
persister cells of P. aeruginosa PAO1 (from cystic fibrosis patients) and E. coli HM22. The
antimicrobial effects of native calcitermin on E. coli and P. aeruginosa has been reported
previously [6] and its short length is considered a favorable characteristics for low cost
manufacturing.
Both the amino acid sequence and local pH can affect the net charge of an AMP [7]. Therefore
by adding more negatively charged amino acids into the sequence of calcitermin, we designed
neutral and negatively charged calcitermin derivatives with the help of Iterative Threading
ASSEmbly Refinement (I-TASSER) Protein Structure & Function Predictions which is available
online [8].

5.2 Materials and Methods

5.2.1 Selecting the candidate AMP to study

To choose the AMP, 277 human originated AMPs chosen from two antimicrobial peptide
databases, Antimicrobial Peptide Database (APD2) and Linking Antimicrobial Peptide (LAMP)
which has 5547 AMPs in total, were compared for their given physiochemical characteristics.
Human originated peptides were selected to minimize cytotoxicity in human body. Some of these
AMPs are shown in (Table 5-1). Calcitermin was selected due to its short size (low production
cost), relatively high hydrophobicity (for amphipathic structure and antimicrobial activity),
relatively low boman index (for less interaction with other proteins), positive charge, origin
tissue (airway secretions), and ɑ-helical structure which is important to target cell membrane.
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Table 5-1. Selected human originated AMPs with some of their important physiochemical characteristics, sources in the body and

Name

Source

Sequence

Net charge

Hydrophobicity

Bowman index

Structure
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Access
number

Length

activities. The data is collected from APD2 and LAMP libraries. G(+); Gram positive bacteria, G(-); Gram negative bacteria.

AP00309
AP00481

KS-27
Kaliocin-1

Skin
Lactoferrin

KSKEKIGKEFKRIVQRIKDFLRNLVPR
FFSASCVPGADKGQFPNLCRLCAGTGENKCA

27
31

7
1

33%
45%

3.38
0.99

Unknown
Unknown

AP00625

KR-20

Sweat

KRIVQRIKDFLRNLVPRTES

20

4

35%

3.68

Helix

AP00626

KS-30

Sweat

KSKEKIGKEFKRIVQRIKDFLRNLVPRTES

30

6

30%

3.47

Helix

AP00627

RK-31

Sweat

RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

31

7

29%

3.83

Helix

AP00628

LL-23

Skin

LLGDFFRKSKEKIGKEFKRIVQR

23

5

34%

3.01

Helix

AP00629
AP00765

LL-29
Salvic

Skin
Saliva

LLGDFFRKSKEKIGKEFKRIVQRIKDFLR
MHDFWVLWVLLEYIYNSACSVLSATSSVSSRVLNR
SLQVKVVKITN

29
46

6
2

37%
50%

2.95
0.7

Helix
Unknown

G(+), G(-),
N/A
G(+), G(-),
Antifungal,
G(+), G(-),
G(+), G(-),
Antifungal,
G(+), G(-),
Antifungal,
G(+), G(-),
N/A

AP00798

Hst1

Saliva

DSHEKRHHGYRRKFHEKHHSHREFPFYGDYGSNY
LYDN

38

0

10%

4.29

H Rich

Antifungal

AP00799

Histatin 2

Saliva

RKFHEKHHSHREFPFYGDYGSNYLYDN

27

0

14%

3.53

H Rich

AP00801

Histatin 6

Saliva

DSHAKRHHGYKRKFHEKHHSHRGYR

25

6

8%

5.21

H Rich

AP00802

Histatin 7

Saliva

RKFHEKHHSHRGY

13

3

7%

5.07

H Rich

AP00803

Histatin 9

Saliva

RKFHEKHHSHRGYR

14

4

7%

5.78

H Rich

AP01407
AP02017

SgI-29
hGAPDH

Sperm
Placenta

HNKQEGRDHDKSKGHFHRVVIHHKGGKAH

29
31

4
5

17%
45%

3.74
1.07

H Rich
Unknown

Antifungal
G(+), G(-),
Antifungal,
Antifungal
G(+), G(-),
Antifungal,
G(+), G(-),
Antifungal

GKVKVGVNGFGRIGRLVTRAAFNSGKVDIVA

Activity

AP02230

HMGN2

Leukocyte

PKRKAEGDAKGDKAKVKDEPQRRSARLSAKPAPP
KPEPKPKKAPAKKGEKVPKGKKGKADAGKEGNNP
AENGDAKTDQAQKAEGAGDAK

89

12

21%

3.2

Unknown

G(-), Antifungal,
Antiviral

AP02343

Beta 2globulin

Amnio

IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIE
VDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTP
TEKDEYACRVNHVTLSQPKIVKWDRDM

99

-2

31%

2.31

Beta

G(+), G(-),
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AP00176

Neutrophil
peptide-1

Neutrophil

ACYCRIPACIAGERRYGTCIYQGRLWAFCC

30

3

53%

1.07

Beta

AP00179

Neutrophil
peptide-4

Neutrophil

VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV

33

4

51%

1.4

Beta

AP00180

Defensin 5

Skin

ATCYCRTGRCATRESLSGVCEISGRLYRLCCR

32

4

40%

2.6

Beta

AP00181

Defensin 6

Skin

AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL

32

2

40%

1.71

Beta

AP00192

Hepcidin 20

Blood

ICIFCCGCCHRSKCGMCCKT

20

3

60%

0.46

Beta

AP00193

LEAP-1

Liver

DTHFPICIFCCGCCHRSKCGMCCKT

25

2

52%

0.89

Beta

AP00196

hBD-26

Skin

42

4

42%

1.58

Bridge

AP00197

hBD-27

Skin

WYVKKCLNDVGICKKKCKPEEMHVKNGWAMCG
KGRDCCVPAD
QLKKCWNNYVQGHCRKICRVNEVPEALCENGRYC
CLNIKELEAC

44

2

43%

2.08

Bridge

AP00283

Beta defensin
3

Skin

GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTR
GRKCCRRKK

45

11

33%

2.87

Helix and
beta

AP00307

Buforin I

Stomach

AGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLL
RKGNY

39

12

28%

3.08

Unknown

AP00310

LL-37,

Neutrophil
skin, sweat,
lung,

LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

37

6

35%

2.99

Helix

G(+), G(-),
Antiviral,
Antifungal,
Antiparasitic,
Cancer cells
G(+), G(-),
Antiviral,
Antifungal,
G(+), G(-),
Antifungal
Antiviral,
Antifungal,
Antifungal,
G(+), G(-),
Antifungal
G(-),
G(-),
G(+), G(-),
Antiviral,
Antifungal,
Chemotactic,
G(+), G(-),
Antifungal
G(+), G(-),
Antiviral,
Antifungal,
Antiparasitic,
Spermicidal,
Chemotactic,
Cancer cells

AP00334

Cathepsin

Neutrophil

IIGGR

1

40%

0.64

Unknown

AP00433

Dermicidin

Sweat

SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGK
GAVHDVKDVLDSV

47

-2

38%

1.11

Helix

AP00449

MSH

Brain

SYSMEHFRWGKPV

13

1

30%

2.01

Unknown

AP00451

hBD-1

Keratinocyte
skin,
platelets

DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCC
K

36

4

36%

1.3

Helix and
beta

AP00504

MUC7 20

Saliva

LAHQKPFIRKSYKCLHKRCR

20

7

35%

3.16

Helix

AP00505

Histatin 5

Parotid
secretion

DSHAKRHHGYKRKFHEKHHSHRGY

24

5

8%

4.81

Helix,
H-rich

AP00509

Calcitermin

VAIALKAAHYHTHKE

15

1

46%

0.89

Helix

G(-), Antifungal

AP00520

Histatin 3,

DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN

32

5

9%

4.72

H-rich

G(+), G(-),
Antifungal

AP00523

Histatin 8

KFHEKHHSHRGY

12

2

8%

4.25

H-rich

GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTK
CCKKP

41

7

36%

0.9

Helix and
beta

38
21
49

6
3
7

36%
9%
32%

2.87
4.84
3.35

Helix
H-rich
bridge

G(+), G(-),
Antifungal
G(+), G(-),
Antiviral,
Antifungal,
Chemotactic,
G(+), G(-),
Antifungal,
G(+), G(-),

49

10

36%

3.14

Helix
Helix and
beta
Bridge

G(+), G(-),
G(+), G(-),
Antifungal
Antifungal,
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5

Airways
secretions
Saliva,
parotid
secretion
Saliva

AP00524

Defensin 2

AP00624
AP00800
AP00675

ALL-38,
Histatin 4,
Defensin 4,

Skin, lung,
trachea
epithelia,
and uterus,
Sperm
Saliva
Skin

AP00780

lactoferricin

Lactoferrin

ALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTE
S
RKFHEKHHSHRGYRSNYLYDN
FELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCL
RKWDESLLNRTKP
GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGP
PVSCIKRDSPIQCIQA

AP00811

LEAP-2

Liver

MTPFWRGVSLRPIGASCRDDSECITRLCRKRRCSLS
VAQE

40

4

40%

2.94

AP00833

Drosomycin

Skin

CLAGRLDKQCTCRRSQPSRRSGHEVGRPSPHCGPS
RQCGCHMD

43

5

25%

3.58

G(+), G(-),
G(+), G(-),
Antifungal
G(+),
Antifungal,
Antiviral,
G(+), G(-),
Antiviral, Cancer
cells
G(+), G(-),
Antifungal
G(+), G(-),
Antiviral,
Antifungal,
Enzyme
inhibitor

G(+), G(-),
Antifungal,
Chemotactic,
Antioxidant,
G(+), G(-),
Antifungal,
Antiparasitic,
Cancer cells
G(+), G(-),

AP00857

Catestatin,

Brain

SSMKLSFRARAYGFRGPGPQL

21

4

33%

1.98

Unknown

AP01161

Granulysin,

Cytolytic t
cells

GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVC
RTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQ
ICEDLR

74

11

33%

3.5

Helix

AP01315

hBD-28

Skin

37

8

40%

1.91

Beta

AP01372

CXCL14,

N/A

ARLKKCFNKVTGYCRKKCKVGERYEIGCLSGKLCC
AN
SKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVI
ITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNE
KRRVYEE

77

13

27%

3.03

Unknown

G(+), G(-),
Antifungal
G(+), G(-),
Antifungal
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68

6

38%

1.72

Helix and
Beta
structure

83

2

36%

1.87

Unknown

29

2

20%

2.85

H-Rich

RPKPQQFFGLM

11

1

36%

1.57

Helix

Brain

ELYENKPRRPYIL

13

3

23%

3.16

Unknown

Bradykinin

Brain

RPPGFSPFR

9

2

22%

2.92

Unknown

Neuropeptide Y

Brain

YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQR
Y

36

1

25%

3

Helix

ECWMDGHCRLLCKDGEDSIIRCRNRKRCC

29

2

41%

3.66

Bridge

ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGS
KAF

37

4

43%

1.08

Helix

Intestine

HSDAVFTDNYTRLRKQMAVKKYLNSILN

28

4

35%

2.48

Unknown

Skin
Skin

YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTD
KDKDNVAPRSKISPQGY
GHHPHGHHPHGHHPHGHHHPH

52
21

6
0

28%
0%

2.6
2.7

Helix
H-Rich

AELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVI
ATLKDGRKICLDPDAPRIKKIVQKKLAGDES

P01373

TC-1

Blood

AP01374

TC-2

Blood

AP01408

SgII

Sperm

NLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQS
LEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKK
IVQKKLAGDES
KQEGRDHDKSKGHFHMIVIHHKGGQAHHG

AP01471

Substance P

Blood

AP01472

Neurotensin,

AP01473
AP01474
AP01475

DEFB120

AP01476

Calcitonin
Vasoactive
polypeptide

AP01477
AP01479
AP01494

Adrenomedullin

GHH20

Pooled
fetal lung,
testis, bcell
Thyroid

G(+), G(-),
Antifungal
G(+), G(-),
G(+), G(-),
Antifungal
G(+), G(-),
Antifungal
G(+), G(-),
Antifungal
G(+), G(-),
Antifungal
G(+), G(-),
Antifungal
G(-), Antifungal
G(+), G(-),
Antifungal
G(+), G(-),
Antifungal,

AP02071

TCP

Skin

NLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGD
ACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDR
DGKYGFYTHVFRLKKWIQKVIDQFGE

96

2

33%

2.15

Unknown

G(+), G(-),
G(+), G(-),
Antiviral,
Antifungal,
Enzyme
inhibitor
G(+), G(-),
Antiviral,
Antifungal
G(+), G(-),
Antiviral,
Antifungal
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AP02072

Elafin

Skin

AQEPVKGPVSTKPGSCPIILIRCAMLNPPNRCLKDT
DCPGIKKCCEGSCGMACFVPQ

57

3

42%

0.94

Beta

AP02073

Abeta40

Brain

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM
VGGVV

40

-3

42%

0.98

Helix

AP02075

Abeta42

Brain

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM
VGGVVIA

42

-3

45%

0.77

Helix

AP02076

RNase 5

Liver,
intestine,
skin

G(+), Antifungal

AP02077

RegIII alpha

Islets,
intestine

AP02078

Psoriasin

AP02079

RNase 7

Skin,
tounge
Skin,
urinary
tract

QDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGP
TSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRIS
KSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVA
CENGLPVHLDQSIFRRPRP
EEPQRELPSARIRCPKGSKAYGSHCYALFLSPKSWT
DADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNS
YSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFA
WERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLP
YVCKFTD
MSNTQAERSIIGMIDMFHKYTRRDDKIDKPSLLTM
MKENFPNFLSACDKKGTNYLADVFEKKDKNEDKK
IDFSEFLSLLGDIATDYHKQSHGAAPCSGGSQ
KPKGMTSSQWFKIQHMQPSPQACNSAMKNINKHT
KRCKDLNTFLHEPFSSVAATCQTPKIACKNGDKNC
HQSHGAVSLTMCKLTSGKYPNCRYKEKRQNKSYV
VACKPPQKKDSQQFHLVPVHLDRVL

AP02080

CCL20

Skin

AP02081

CXCL1

Bone
marrow

AP02082

CXCL2

Bone
marrow

AP02083

CXCL3

Bone
marrow

125

11

28%

2.99

Helix and
Beta
structure

149

1

33%

1.77

Helix and
Beta
structure

G(+),

101

-1

32%

2.3

Helix

G(-),
Chemotactic

128

16

32%

2.16

SNFDCCLGYTDRILHPKFIVGFTRQLANEGCDINAII
FHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM

69

8

43%

1.34

ASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCA
QTEVIATLKNGRKACLNPASPIVKKIIEKMLNSDKS
N

73

6

38%

1.51

APLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCA
QTEVIATLKNGQKACLNPASPMVKKIIEKMLKNGK
SN

73

8

39%

1.17

ASVVTELRCQCLQTLQGIHLKNIQSVNVRSPGPHCA
QTEVIATLKNGKKACLNPASPMVQKIIEKILNKGST
N

73

6

39%

1.27

Helix and
Beta
structure
Helix and
Beta
structure
Helix and
Beta
structure
Helix and
Beta
structure
Unknown

G(+), G(-),
Antifungal
G(+), G(-),
Antifungal,
Antiparasitic,
G(+), G(-),
Chemotactic
G(+), G(-),
Antiparasitic,
Chemotactic,
G(+), G(-),
Chemotactic

175

AP02084

CXCL9

Bone
marrow

AP02085

CXCL10

Bone
marrow

AP02086

CXCL11

Bone
marrow

AP02087

CXCL12

Stomach

AP02088

CXCL13

Stomach

AP02089

XCL1

Stomach

AP02090

I-309,

Lymphocyte

AP02091

MCP-2,

AP02092

G(+), G(-),
Antiparasitic,
Chemotactic,
G(+), G(-),
Antifungal,
Antiparasitic,

TPVVRKGRCSCISTNQGTIHLQSLKDLKQFAPSPSCE
KIEIIATLKNGVQTCLNPDSADVKELIKKWEKQVSQ
KKKQKNGKKHQKKKVLKVRKSQRSRQKKTT

103

20

28%

2.7

VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPR
VEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSK
RSP

77

11

36%

2.25

FPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNN
CDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKN
F

73

11

41%

1.83

KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCAL
QIVARLKNNNRQVCIDPKLKWIQEYLEKALNK

68

9

42%

1.93

87

11

41%

2.1

Unknown

93

9

32%

2.41

Beta

KSMQVPFSRCCFSFAEQEIPLRAILCYRNTSSICSNE
GLIFKLKRGKEACALDTVGWVQRHRKMLRHCPSK
RK

73

10

41%

2.25

Macrophage

PDSVSIPITCCFNVINRKIPIQRLESYTRITNIQCPKEA
VIFKTKRGKEVCADPKERWVRDSMKHLDQIFQNL
KP

75

6

37%

2.27

Eotaxin,

Eosinophil

GPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQ
KAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSP
TPKP

74

11

33%

2.03

AP02093

MCP-4,

Macrophage

QPDALNVPSTCCFTFSSKKISLQRLKSYVITTSRCPQ
KAVIFRTKLGKEICADPKEKWVQNYMKHLGRKAH
TLKT

75

11

36%

1.89

AP02094

TARC,

Platelet

ARGTNVGRECCLEYFKGAIPLRKLKTWYQTSEDCS
RDAIVFVTVQGRAICSDPNNKRVKNAVKYLQSLER
S

71

6

36%

2.42

AP02095

PARC,

Platelet

AQVGTNKELCCLVYTSWQIPQKFIVDYSETSPQCPK
PGVILLTKRGRQICADPNKKWVQKYISDLKLNA

69

5

37%

1.39

Unknown

G(+), G(-),
Chemotactic

AP02096

MIP-3

Leukocyte

GTNDAEDCCLSVTQKPIPGYIVRNFHYLLIKDGCRV
PAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAK
MKRRSS

77

7

37%

2.23

Unknown

G(-),
Chemotactic

VLEVYYTSLRCRCVQESSVFIPRRFIDRIQILPRGNG
CPRKEIIVWKKNKSIVCVDPQAEWIQRMMEVLRKR
SSSTLPVPVFKRKIP
VGSEVSDKRTCVSLTTQRLPVSRIKTYTITEGSLRA
VIFITKRGLKVCADPQATWVRDVVRSMDRKSNTR
NNMIQTKPTGTQQSTNTAVTLTG

Unknown
Helix and
Beta
structure
Helix and
Beta
structure
Helix and
Beta
structure

Helix and
Beta
structure
Helix and
Beta
structure
Helix and
Beta
structure
Helix and
Beta
structure
Helix and
Beta
structure

G(+), G(-),
Chemotactic
G(+), G(-),
Antiviral
G(+), G(-),
Chemotactic
G(+), G(-),
Chemotactic
G(+), G(-),
Chemotactic
G(-),
Chemotactic
G(+), G(-),
Chemotactic
G(-),
Chemotactic
G(+), G(-),
Chemotactic

AP02097

TECK,

Leukocyte

127

15

37%

1.81

Unknown

G(+), G(-),
Chemotactic
G(+), G(-),
Chemotactic

111

16

27%

2.65

Helix and
Beta
structure

GPYGANMEDSVCCRDYVRYRLPLRVVKHFYWTSD
SCPRPGVVLLTFRDKEICADPRVPWVKMILNKLSQ

69

4

40%

1.85

Unknown

SLPI

Saliva,
Airway

SGKSFKAGVCPPKKSAQCLRYKKPECQSDWQCPG
KKRCCPDTCGIKCLDPVDTPNPTRRKPGKCPVTYG
QCLMLNPPNFCEMDGQCKRDLKCCMGMCGKSCV
SPVKA

107

12

34%

1.87

Beta

UBI 1-59

Small
intestine

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAK
RRMQYNRRFVNVVPTFGKKKGPNANS

59

19

25%

3.28

Unknown

G(+), G(-),

RNase 8

Urinary
tract

KPKDMTSSQWFKTQHVQPSPQACNSAMSIINKYTE
RCKDLNTFLHEPFSSVAITCQTPNIACKNSCKNCHQ
SHGPMSLTMGELTSGKYPNCRYKEKHLNTPYIVAC
DPPQQGDPGYPLVPVHLDKVV

127

4

31%

1.7

Unknown

G(+), G(-),
Antifungal

133

13

36%

2.71

Helix and
Beta
structure

AP02099

SLC,

Leukocyte

AP02158

MDC,

Leukocyte

AP02182

AP02184
AP02185

QGVFEDCCLAYHYPIGWAVLRRAWTYRIQEVSGSC
NLPAAIFYLPKRHRKVCGNPKSREVQRAMKLLDAR
NKVFAKLHHNTQTFQAGPHAVKKLSSGNSKLSSSK
FSNPISSSKRNVSLLISANSGL
SDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSI
PAILFLPRKRSQAELCADPKELWVQQLMQHLDKTP
SPQKPAQGCRKDRGASKTGKKGKGSKGCKRTERS
QTPKGP

176
AP02186

ECP

Eosinophilic
leukocytes

RPPQFTRAQWFAIQHISLNPPRCTIAMRAINNYRWR
CKNQNTFLRTTFANVVNVCGNQSIRCPHNRTLNNC
HRSRFRVPLLHCDLINPGAQNISNCTYADRPGRRFY
VVACDNRDPRDSPRYPVVPVHLDTTI

AP02187

hPF4

Platelet

EAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHC
PTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES

70

3

40%

1.46

Unknown

AP02195

DEFB114

DRCTKRYGRCKRDCLESEKQIDICSLPRKICCTEKL
YEEDDMF

43

0

32%

3.58

Bridge

AP02196

Alarin

Gingival
cells
Brain

APAHRSSTFPKWVTKTERGRQPLRS

25

5

24%

3.47

Unknown

AP02231

CXCL6

Bone
marrow

GPVSAVLTELRCTCLRVTLRVNPKTIGKLQVFPAGP
QCSKVEVVASLKNGKQVCLDPEAPFLKKVIQKILD
SGNKKN

77

8

41%

1.14

Unknown

Kinocidin

Saliva,
milk,
epithelial
cells/mucos
al tissues

MQQRGLAIVALAVCAALHASEAILPIASSCCTEVSH
HISRRLLERVNMCRIQRADGDCDLAAVILHVKRRRI
CVSPHNHTVKQWMKVQAAKKNGKGNVCHRKKH
HGKRNSNRAHQGKHETYGHKTPY

AP02257

127

16

39%

2.3

Unknown

G(+), G(-),
Chemotactic
G(+), G(-),
Antiviral,
Antifungal,
Enzyme
inhibitor,

G(+), G(-),
Antiviral,
Antiparasitic,
Mammalian
cells,
Antiparasitic,
Antimalarial,
G(+), G(-),
Antifungal
G(-),
G(+), G(-),
Antiparasitic,
Chemotactic,
G(+), G(-),
Antifungal,
Antiparasitic,
Chemotactic,

AP02337

CCL27

Brain

AP02409

Chemerin

Epidermis,
skin,

AP02425
AP02451

hIAPP,
KDAMP 10

Islets
Cornea

AP02452

Lysozyme

Secretions
and tissues

PPSTACCTQLYRKPLSDKLLRKVIQVELQEADGDC
HLQAFVLHLAQRSICIHPQNP
ELTEAQRRGLQVALEEFHKHPPVQWAFQETSVESA
VDTPFPAGIFVRLEFKLQQTSCRKRDWKKPECKVR
PNGRKRKCLACIKLGSEDKVLGRLVHCPIETQVLRE
AEEHQETQCLRVQRAGEDPHSFYFPGQFAFS
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNT
Y
RAIGGGLSSVGGGSSTIKY
KVFERCELARTLKRLGMDGYRGISLANWMCLAKW
ESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGK
TPGAVNACHLSCSALLQDNIADAVACAKRVVRDP
QGIRAWVAWRNRCQNRDVRQYVQGCGV

56

1

41%

1.57

Helix and
Beta
structure

137

3

36%

2.38

Unknown

37
19

3
2

37%
26%

1.48
0.55

Helix
Unknown

130

8

40%

2.28

Helix

Antifungal,
Chemotactic
G(+), G(-),
Antifungal,
Chemotactic,
G(+), G(-),
G(-),
G(+), G(-),
Antifungal
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5.2.2 Designing new calcitermin derivatives with different net charges
We used I-TASSER to design neutral and negatively charged derivatives of calcitermin based on
the original amino acid sequence; VAIALKAAHYHTHKE. This prediction method helped us to
keep α-helical structure of calcitermin during designing process. First, positively charged Lys
(K), at position 14, residue was replaced with Gly (G) to obtain a neutral AMP derivative
VAIALKAAHYHTHGE (0). Then Ala (A), at position 8 was replaced with a negatively charged
Glu (E) for AMP derivative with a net charge of “-1”, VAIALKAEHYHTHGE. Finally, an Ala
(A) at position 4 residue was replaced with Glu (E) to obtain an AMP with a net charge of “-2”,
VAIELKAEHYHTHGE. Each amino acid change was individually confirmed to ensure no
change in the amphipaticity and the ɑ-helical structure. The helical wheel projection model was
used to retain protect amphiphilic topology during design studies. These derivatives were also
checked for their net charges at slightly acidic conditions (pH 5.5) to mimic the CF airways.

5.2.3 Killing effects of calcitermin and its derivatives on planktonic cells at pH 7.4 and
pH 5.5
To examine the antimicrobial activity of calcitermin and its neutral derivative, the planktonic
cultures of E. coli HM22, and P. aeruginosa PAO1 were treated. The pH values 5.5 and 7.4 were
studied to resemble the nasal airway conditions in cystic fibrosis patients and healthy individuals
respectively. Overnight cultures of each strain were grown in 50 mL LB medium for 12-16 h at
37°C. Subcultures were then prepared by inoculating LB medium with overnight cultures to an
optical density at 600 nm (OD600) of 0.01 and harvested when the OD600 reached 0.4-0.5. These
exponential cultures were divided into two sample groups; to be washed with PBS (pH 7.4) and
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PBS (pH 5.5 with HCl), and resuspended in the same buffer after washing. For the treatment
with calcitermin and its neutral derivative, 3 mL of each sample was taken and mixed with
different concentrations of calcitermin. The samples were incubated for 3 h at 37°C with shaking
at 200 rpm, and washed three times with PBS at pH 7.4 and pH 5.5. Then a serial dilution of
each sample was prepared to obtain the concentrations from 1 to 100µg/mL. The cells were then
washed again and spread on LB agar plates for counting CFU. Each condition was tested with
three independent cultures.

5.2.4 Persister isolation and calcitermin treatment at pH 7.4 and pH 5.5
To isolate persister cells, overnight cultures of P. aeruginosa PAO1 and exponential cultures of
E. coli HM22 strains were treated with 200 µg/mL ciprofloxacin (Cip) and 100 µg/mL ampicillin
respectively for 3 h at 37˚C to kill normal cells as described previously [9,10]. Then the persister
cells were harvested by centrifugation, washed with PBS at different pH values (pH 7.4 and pH
5.5 with HCl) three times to remove remaining antibiotic, and resuspended in 20 mL PBS at pH
7.4 and 5.5. The collected cells were resuspended in 3 mL PBS supplemented with calcitermin at
different concentrations (from 1 to 100µg/mL). Three replicates were tested for each condition
and all samples were incubated for 3 h at 37°C with shaking at 200 rpm. After calcitermin
treatment, the samples were washed with PBS three times and plated to count CFU using drop
plate method.
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5.3 Results
5.3.1 New calcitermin derivatives designed with I-TASSER prediction method

Neutral and negatively charged AMP derivatives of calcitermin were successfully designed by
replacing amino acids guided by helical wheel projections (Fig. 5-1). The amphiphilic topology
and the helical structure of each derivative were tested with I-TASSER prediction method. Lys
(K), which is a positively charged amino acid at position 14, was replaced with Gly (G), a neutral
amino acid, and the net charge of the peptide changed from “+1” to “0” without altering the 3D
structure of calcitermin. Besides, changing positions 4 and 8 to Glu (E) was found to protect the
ɑ-helix conformation (Fig 5-1) but changed the net charge of calcitermin to negative. Besides,
prediction analysis with I-TASSER suggested a candidate binding region for Ca2+ ions (Fig. 52). This binding region is surrounded by three His (H) at positions 9, 11, 13 and one Tyr (Y) 12.
In derivative design this Ca2+ion binding region was successfully retained in all calcitermin
derivatives.

A)

B)

C)

D)

E)

Figure 5-1. A) Helical wheel projection of calcitermin. Modified amino acid positions are
colored gray. B) Native calcitermin VAIALKAAHYHTHKE (+1), C) neutral derivative
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VAIALKAAHYHTHGE (0), D) negatively charged VAIALKAEHYHTHGE (-1), E) negatively
charged VAIELKAEHYHTHGE (-2). Modified amino acids are underlined along the new net
charges are shown in parenthesis.

Figure 5-2. Predicted Ca2+ binding site on the native calcitermin from different angles. Green
sphere represent Ca2+ ion. The blue part, which shows Ca2+ ion binding pocket, is rich with
amino acids carrying carbon rings in their structures.

5.3.2 Killing effects of calcitermins on planktonic cells

Native calcitermin is effective in killing PAO1 and HM22 cells at pH 5.5 dose dependently.
However, no significant killing effect was observed when pH in calcitermin treatment elevated to
pH 7.4 (Fig. 5-3). This is consistent with the in vivo observation that pH is 5.5 in chronic disease
condition. Calcitermin showed significant killing on both PAO1 and HM22 planktonic cells at
pH 5.5 when its concentration is increased to 10µg/mL and higher.
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Figure 5-3. Antimicrobial effect of native calcitermin on the planktonic cells of P. aeruginosa
PAO1 and E. coli HM22 strains. Both strains were tested at pH 7.4 and pH 5.5.

The killing effect of neutral calcitermin derivative on planktonic cells was found different than
the native calcitermin. Neutral calcitermin derivative showed comparable killing with a dose
dependence when the experiment pH was adjusted to pH 7.4 (Fig. 5-4). However, this killing
was not as significant as native calcitermin.
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Figure 5-4. Antimicrobial effects of neutral calcitermin derivative on planktonic cells of P.
aeruginosa PAO1 and E. coli HM22 strains. Both strains were tested at pH 7.4 and pH 5.5.

5.3.3 Killing effects of calcitermins on persister cells

Even though the total killing is less than normal planktonic cells, native calcitermin was found
effective against the persister cells of both strains and the effect was stronger at pH 5.5 than pH
7.4 (Fig 5-5). On the other hand, neutral derivative of calcitermin showed stronger effect on both
P. aeruginosa PAO1 and E. coli HM22 persister cells at pH 7.4 than pH 5.5 (Fig. 5-6).
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The killing effect of the neutral derivative on persister cells are rather potent, e. g., 83.35±5.2%
and 96.54±2.3% of P. aeruginosa PAO1 and E. coli HM22 persister cells were killed at 100
µg/mL respectively.

Figure 5-5. Antimicrobial effects of native calcitermin on persister cells of P. aeruginosa PAO1
and E. coli HM22 strains. Both strains were tested at pH 7.4 and pH 5.5.
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Figure 5-6. Antimicrobial effects of neutral calcitermin derivative on persister cells of P.
aeruginosa PAO1 and E. coli HM22 strains. Both strains were tested at pH 7.4 and pH 5.5.

5.4 Discussion

The amphiphilic topology and ɑ-helical structure were successfully maintained for the new
calcitermin derivatives by using I-TASSER prediction method. These two physiochemical
features of this AMP are required for insertion into bacterial cell membrane and for the
antimicrobial effects [2]. To protect ɑ-helical structure, amino acid changes were made based on
their ɑ-helix formation propensities. Prediction studies showed that replacing Gly (G) at position
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14 did not cause any change in the on ɑ-helix structure. This amino acid was chosen to change
the net charge of new calcitermin derivative since there are only two amino acids with negatively
charged side chains: Gly (G) and Ala (A). These two amino acids are also members in the family
of high helix forming propensity amino acids, while the others are with Met (M), Leu (L) and
Lys (K) [11]. This high helix forming propensity of Gly (G) might have helped the unimpaired
ɑ-helix structure of new derivatives. However, replacing positions 4 and 8 with Ala (A) caused
deterioration of the ɑ-helix structures for new designs even though Ala (A) is a high helix
forming propensity amino acid.
Another important factor for the antimicrobial effects of calcitermin is the binding of Ca2+ ions,
which were also demonstrated by I-TASSER predictions (Fig 5-2). The calcitermin sequence is
equivalent to 15 amino acid carboxyl end of a calgranulin, S100 [5] which are also called
calcium binding proteins (CaBP) [12]. S100 proteins, involved in Ca2+ homeostasis [13], are also
found in vertebrates and characterized by two calcium-binding sites with ɑ-helix structures [14].
Ion binding regions are known to be important for the function of many peptides [15].
Calcitermin derivatives designed with I-TASSER were shown to preserve Ca2+ ion binding
pocket. Ca2+ ions are also known as important for the integrity of membrane lipid bilayer
structure [15]. This Ca2+ ion binding capacity of calcitermin might affect stability of the
membrane since Ca2+ ions are important for membrane integrity. Therefore, calcitermin
derivatives might still hold potential to bind Ca2+ ions and be effective on the membrane
stability.
The amino acids in Ca2+ binding pocket of calcitermin have either 5 carbon ring as in His (H) or
6 carbon ring as in Tyr (Y). Some Ca2+ binding proteins are known His (H) rich peptides [16].
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This suggests that having three His (H) amino acids close to each other within a 5 amino acid
region is important for the Ca2+ binding ability of calcitermin. During new derivative design
studies these amino acids involved in Ca2+ binding pocket were retained to protect the Ca2+
binding capacity of the peptide.
It was shown that antimicrobial activity of calcitermin is enhanced in acidic environment (pH
5.4) [5]. In addition, the native calcitermin, which is positively charged, showed significant
killing of P. aeruginosa PAO1 and E. coli HM22 cells in exponential cultures only at pH 5.5, but
not effective at pH 7.4 (Fig 5-3). For example, the killing on P. aeruginosa PAO1 exponential
cultures by ratios with 10, 50, and 100 µg/mL calcitermin was 49.63±6.24%, 90.72±7.6%, and
95.27±3.28%, while it showed slightly higher killing effect on E. coli HM22 exponential cells,
e.g., 66.08±12.07%, 97.07±2.31%, and 99.46±3.98% at the same concentrations. Similar to
planktonic cells, native calcitermin showed comparable effects on persister cells; better killing at
pH 5.5 while no clear effect was observed at pH 7.4 (Fig 5-5). For example at 50 and 100
µg/mL, calcitermin was able to kill 25.29±3.57% and 48.82±3.6% P. aeruginosa PAO1 persister
cells respectively. Persister cells of E. coli HM22 showed similar susceptibility to native
calcitermin and the killing was 34.1±3.8% and 60.13±9.7% at 50 and 100 µg/mL respectively.
Even though it is less effective than killing normal planktonic cells, the killing effect of native
calcitermin on persister cells holds a potential, which might be further improved via co-treatment
with other antibiotics. Besides comparable killing effects of native calcitermin on the normal and
persister cells of both strains, a general mechanism of action might be cell membrane targeting
since E. coli is more susceptible to antibiotics in general [17].
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The neutral calcitermin derivative did show strong killing effect on normal planktonic cells of P.
aeruginosa PAO1 and E. coli HM22 at pH 7.4 compared native calcitermin. However, this new
derivative showed similar effects at pH 7.4 and pH 5.5. For example, 100 µg/mL neutral
calcitermin derivative killed 35.71±3.52% and 45.41±5.71% of normal planktonic PAO1 cells at
pH 5.5 and pH 7.4 respectively. Similarly, the neutral calcitermin derivative showed slightly
better killing effect on E. coli HM22 planktonic cells at pH 7.4 compared to pH 5.5; e.g.,
28.33±5.97% and 48.62±2.96% with pH 5.5, and 42.18±8.72% and 60.46±6.3% with pH 7.4, at
50 and 100µg/mL, respectively. The trend of less killing effect at lower pH diminished when the
neutral calcitermin derivative was tested on persister cells of P. aeruginosa PAO1 and E. coli
HM22. However, a significantly higher killing effect with pH 7.4 on persister cells compared to
planktonic cells of both strains was observed when treated with neutral calcitermin derivative.
For example, 10, 50, and 100 µg/mL neutral calcitermin showed 31.3±8.23, 62.22±7.1%, and
83.35±5.2% killing of PAO1 and 42.37±5.08%, 72.58±1.92%, and 96.54±2.3% killing of HM22
respectively.
Persister cells provide a reservoir for recurring infections [18]. As an effective AMP at pH 7.4,
which is the pH level of nasal airways in healthy people, calcitermin might be able to eliminate
persister cells before the infection becomes chronic. Another important outcome from this study
is the finding that the neutral derivative is more effective on persister cells than its positively
charged native form. We expect that other AMPs can be engineered following this principle to
achieve better control of chronic infections. Besides, the higher killing effect of neutral
calcitermin derivative on persister cells might be further improved by combining it with the
native form or via co-treatment with other antimicrobial agents so that both normal and persister
cells can be eliminated.
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CHAPTER 6

CONCLUSION AND FUTURE WORK
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As alternative antimicrobials, AMPs have advantages since these compounds attack bacterial
membranes and thus have a broad spectrum of targeting microbes. Cell membrane is present in
all bacteria with a relatively simple bilayer structure. The functions of membrane embedded
proteins that are essential for the survival of bacteria and the rapid action of AMPs leave little
room for bacteria to develop resistance. These properties led to growing interest in AMP
research and some novel lead compounds have shown great potential for infection control.
However, the lack of a methodology for rational AMP design, high production cost,
susceptibility to proteolytic degradation, potential toxicity to eukaryotic cells and low specify for
a given bacterial species are the major challenges in AMP development which need to be
addressed in new design studies. Therefore, more research on the mechanisms of AMP killing an
the design of synthetic AMPs are required.
Up to date, most of the AMP studies focused on planktonic cells. Treatment of biofilms and
persister cells, that are highly resistant to traditional antibiotics, with AMPs is still an
understudied area. Through collaboration with the Kallenbach lab at New York University, we
tested the newly designed synthetic AMPs for their activities against bacterial cells at different
physiological stages including normal planktonic cells, persister cells and biofilms.
RW rich peptides are known to be effective on bacterial cells. Here we demonstrated that 2D-24,
a new RW rick dendrimer with a branched core is effective on multidrug-tolerant persister cells
of P. aeruginosa PAO1 and PDO300 in a dose dependent manner with no toxicity to eukaryotic
cells at the effective concentrations. Besides, changing the net charge of calcitermin from +1 to
neutral resulted in a better killing of persister cells at neutral pH. Triazine derivatives were also
proven effective on normal planktonic and persister cells as well as biofilm cells (in the presence
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of alginate lyase). These results show that AMPs can be engineered with optimized structure for
better killing of multi-drug tolerant bacteria at different physiological stages. It is also possible to
achieve synergy with conventional antibiotics in bacterial killing with lowered cytotoxicity to
eukaryotic cells.
The structure-function relation of effective AMP derivatives at different pH values and cellular
stages might be studied to further develop AMPs for different clinical applications.
In addition to membrane targeting AMPs, we also tested some antibiotics that are substrates of
efflux pumps on persister cells. Erythromycin was found effective on E. coli HM22 persister
cells, although the normal planktonic cells are resistant to this antibiotic. This antibiotic is a
known substrate of the efflux pump AcrAB and these pumps are active in normal planktonic
cells. For persister cells, these efflux pumps are inactive and erythromycin molecules can
accumulate in cytoplasm. The strong binding between erythromycin and bacterial ribosome may
lead to killing of persister cells during wake-up process.
Human originated AMPs are a great source for developing new control agents to treat different
infections. Different physiological conditions of different tissues might limit or hinder the
effectiveness of a particular AMP for certain infections. Therefore, designing different AMP
structures specific for different tissues will be a useful strategy for future studies.
In addition to the bacterial killing, the diverse antimicrobial and structural properties of AMPs
make them a convenient tool for other biological applications such as drug delivery vehicles. The
close interaction between AMP with membrane can be used to deliver other therapeutic agents
through the membrane. For example chloramphenicol requires active transport for cellular
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uptake. These transport mechanism are expected to be inactive in persister cells. Using AMPchloramphenicol hybrids to deliver these drugs to persister cells may lead to enhanced
antimicrobial activity. Thus, understanding the biological and structure properties of AMPs and
their interaction with bacterial membranes is important for developing peptide-based
therapeutics.
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